{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "import nltk\n",
    "from nltk.corpus import state_union\n",
    "from nltk.tokenize import RegexpTokenizer\n",
    "from nltk.corpus import stopwords\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import nltk\n",
    "#from bs4 import BeautifulSoup\n",
    "import re\n",
    "import os\n",
    "import codecs\n",
    "from sklearn import feature_extraction\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "#import mpld3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [],
   "source": [
    "var1 = open('C16014.txt').read().split('\\n')\n",
    "var2 = open('C16038.txt').read().split('\\n')\n",
    "#var3 = open('TAK3.txt').read().split('\\n')\n",
    "corpus = [var1,var2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk.corpus import stopwords\n",
    "#from nltk.tokenize import sent_tokenize\n",
    "from nltk.tokenize import sent_tokenize, word_tokenize\n",
    "from nltk.tokenize import RegexpTokenizer\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [],
   "source": [
    "def dtokenize(txts):\n",
    "    #tokenizer = RegexpTokenizer(r'\\w+')\n",
    "    stop_words = set(stopwords.words('english'))\n",
    "    dlist = []\n",
    "    for i in txts:\n",
    "        # low = i.lower()\n",
    "        #tokens = tokenizer.tokenize(low)\n",
    "        #word_tokens = word_tokenize(i)\n",
    "        word_tokens = sent_tokenize(i)\n",
    "        filtered_token = [w for w in word_tokens if not w in stop_words]\n",
    "        for token in filtered_token:\n",
    "            if re.search('[a-zA-Z]', token):\n",
    "                dlist.append(token.lower())\n",
    "        #if re.search('[a-zA-Z]', filtered_token):\n",
    "        #dlist.append(filtered_token)\n",
    "    return dlist"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [],
   "source": [
    "def dCorpus(corpus):\n",
    "    #stop_words = set(stopwords.words('english'))\n",
    "    dCorpus = []\n",
    "    for i in corpus:\n",
    "        #word_tokens = word_tokenize(i)\n",
    "        #filtered_token = [w for w in word_tokens if not w in stop_words]\n",
    "        filtered_token = dtokenize(i)\n",
    "        dCorpus.append(filtered_token)\n",
    "    return dCorpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "lst = dCorpus(corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'2'"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "str(len(lst))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[', eudract:  2013-000326-54',\n",
       " 'a phase 3, randomized, double-blind, multicenter study comparing oral',\n",
       " 'plus lenalidomide and dexamethasone versus placebo plus lenalidomide and',\n",
       " 'dexamethasone in adult patients with newly diagnosed multiple myeloma',\n",
       " 'protocol number:',\n",
       " 'indication:',\n",
       " 'phase:',\n",
       " 'sponsor:',\n",
       " 'eudract number:',\n",
       " 'therapeutic area:',\n",
       " 'protocol history',\n",
       " 'original',\n",
       " 'approved by:',\n",
       " 'c16014',\n",
       " 'newly diagnosed multiple myeloma',\n",
       " 'millennium pharmaceuticals, inc.',\n",
       " 'oncology',\n",
       " '14 february 2013',\n",
       " 'millennium pharmaceuticals, inc.',\n",
       " '40 landsdowne street',\n",
       " 'cambridge, ma  usa  02139',\n",
       " 'telephone:  +1 (617) 679-7000',\n",
       " 'note:  if this document was approved electronically, the electronic approval signatures may',\n",
       " 'be found at the end of the document.',\n",
       " 'dixie-lee esseltine, md',\n",
       " 'vice president, oncology clinical research',\n",
       " '(or designee)',\n",
       " 'signature',\n",
       " 'date dd month yyyy',\n",
       " 'ai-min hui, md, phd',\n",
       " 'global clinical lead (or designee)',\n",
       " 'signature',\n",
       " 'date dd month  yyyy',\n",
       " 'confidentiality statement',\n",
       " 'the information contained herein is confidential and the proprietary property of millennium',\n",
       " 'pharmaceuticals and any unauthorized use or disclosure of such information without the prior',\n",
       " 'written authorization of millennium pharmaceuticals is expressly prohibited.',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'protocol summary',\n",
       " 'study title:  a phase 3, randomized, double-blind, multicenter study comparing oral',\n",
       " 'plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in',\n",
       " 'adult patients with newly diagnosed multiple myeloma',\n",
       " 'study phase:  3',\n",
       " 'number of patients: approximately 701',\n",
       " 'study objectives',\n",
       " 'primary objective:',\n",
       " '\\uf0b7 to determine whether the addition of oral  to lenalidomide and dexamethasone',\n",
       " 'improves progression-free survival (pfs) in patients with newly-diagnosed multiple myeloma',\n",
       " '(ndmm)',\n",
       " 'key secondary objectives:',\n",
       " '\\uf0b7 to determine whether the addition of oral  to lenalidomide and dexamethasone',\n",
       " 'improves the rate of complete response (cr)',\n",
       " '\\uf0b7 to determine whether the addition of oral  to lenalidomide and dexamethasone',\n",
       " 'improves overall survival (os)',\n",
       " '\\uf0b7 to determine whether the addition of oral  to lenalidomide and dexamethasone',\n",
       " 'improves pain response rate, as assessed by the brief pain inventory – short form (bpi-sf)',\n",
       " 'and analgesic use',\n",
       " 'other secondary objectives:',\n",
       " '\\uf0b7 to determine overall response rate (orr), including partial response (pr), very good partial',\n",
       " 'response (vgpr), and cr',\n",
       " '\\uf0b7 to determine time to response (ttr), duration of response (dor), and time to progression',\n",
       " '(ttp)',\n",
       " '\\uf0b7 to determine the safety of the addition of  to lenalidomide and dexamethasone',\n",
       " '\\uf0b7 to assess change in global health status, as measured by the global health status, functioning,',\n",
       " 'and symptoms as measured by the patient-reported outcome (pro) instrument european',\n",
       " 'organization for research and treatment of cancer quality of life questionnaire (eortc',\n",
       " 'qlq-c30) and my-20 module',\n",
       " '\\uf0b7 to determine the pfs and os in high-risk cytogenetic patient groups defined by the',\n",
       " 'following cytogenetic abnormalities: t(4;14), t(14;16), +1q, and del(17)',\n",
       " '\\uf0b7 to evaluate the relationship between polymorphisms in proteasome and nfkb-related genes,',\n",
       " 'such as psmb1 and traf-3, or circulating proteasome levels, and response, dor and pfs,',\n",
       " 'using blood samples',\n",
       " '\\uf0b7 to evaluate the frequency of detection of minimal residual disease via flow cytometry in',\n",
       " 'patients assessed at cr and its impact on pfs and os',\n",
       " '\\uf0b7 to assess time to pain progression',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " '\\uf0b7 to collect pharmacokinetic (pk) data to contribute to population pk analyses',\n",
       " '\\uf0b7 to evaluate the frequency of skeletal-related events (eg, new fractures [excluding vertebral',\n",
       " 'compression or rib fractures], irradiation of or surgery on bone, or spinal cord compression)',\n",
       " 'from baseline through the last survival assessment',\n",
       " 'exploratory objectives:',\n",
       " '\\uf0b7 to evaluate health utilization (hu) and collect euroqol 5-dimensional health questionnaire',\n",
       " '(eq-5d)',\n",
       " '\\uf0b7 to assess time to pain response and duration of pain response',\n",
       " '\\uf0b7 to evaluate the potential relationship between response/ resistance and patient outcome to',\n",
       " ' treatment and mutations in any key signaling pathways determined to be clinically',\n",
       " 'meaningful, such as ras/raf, using bone marrow aspirates',\n",
       " '\\uf0b7 to evaluate the potential relationship between response/ resistance and patient outcome to',\n",
       " ' treatment and tumor gene expression patterns including nfkb and protein',\n",
       " 'synthesis signatures, as well as pathway signatures or transcript levels determined to be',\n",
       " 'clinically meaningful, using bone marrow aspirates',\n",
       " '\\uf0b7 to evaluate potential mechanisms of treatment-emergent resistance, such as somatic',\n",
       " 'mutations in proteasome subunits and in key signaling pathways, or change in pathways',\n",
       " 'activity, in tumors that initially respond to therapy and then exhibit progressive disease',\n",
       " '\\uf0b7 to evaluate the effects of  therapy on changes in bone mineral density as assessed',\n",
       " 'by dual-energy x-ray absorptiometry (dexa) and changes in bone metabolism biomarkers',\n",
       " 'such as srankl/opg and dkk-1 levels using blood samples',\n",
       " '\\uf0b7 to evaluate the resolution and improvement of peripheral neuropathy (pn), if it occurs, by',\n",
       " 'grading at each subsequent monthly visit until 1) resolution of peripheral neuropathy, 2) the',\n",
       " 'start of an alternative antineoplastic treatment, or 3) 6 months after progression has occurred,',\n",
       " 'whichever comes first',\n",
       " 'overview of study design:',\n",
       " 'this is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of',\n",
       " ' versus placebo when added to lenalidomide and dexamethasone (lendex) in patients',\n",
       " 'with ndmm.',\n",
       " 'adult patients with a confirmed diagnosis of symptomatic multiple myeloma (mm)',\n",
       " 'who have not received previous anti-myeloma treatment, who are ineligible for high-dose therapy',\n",
       " 'plus stem cell transplantation (hdt-sct) because of age (ie, \\uf0b3 65 years) or coexisting conditions',\n",
       " 'per investigator judgment, who are candidates for treatment with lendex as their standard therapy,',\n",
       " 'and who meet other eligibility criteria detailed in section 5 will be enrolled in this study.',\n",
       " 'following the screening period, patients to be enrolled will be randomized to receive either',\n",
       " ' or placebo in a double-blind fashion in addition to the background therapy of lendex.',\n",
       " 'eligible patients will be randomized in a 1:1 ratio into those 2 treatment arms, stratified by age',\n",
       " '(\\uf03c 75 years vs \\uf0b3 75), international staging system (iss) (stage 1 or 2 vs stage 3), and bpi-sf worst',\n",
       " 'pain score (\\uf03c 4 vs \\uf0b3 4) at screening.',\n",
       " 'patients will receive oral  4.0 mg or a matching placebo capsule on days 1, 8, and 15 plus',\n",
       " 'lenalidomide (25 mg) on days 1 through 21 and dexamethasone (40 mg) on days 1, 8, 15, and 22 of',\n",
       " 'a 28-day cycle.',\n",
       " 'patients over 75 years of age will receive a reduced dexamethasone dose (20 mg).',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'dose modifications may be made throughout the study based on toxicities.',\n",
       " 'patients with a low',\n",
       " 'creatinine clearance \\uf0a3 60 ml/min (or \\uf0a3 50 ml/min, according to local label/practice) will receive a',\n",
       " 'reduced lenalidomide dose of 10 mg once daily on days 1 through 21 of a 28-day cycle.',\n",
       " 'the',\n",
       " 'lenalidomide dose may be escalated to 15 mg once daily after 2 cycles if the patient is not',\n",
       " 'responding to treatment and is tolerating the treatment.',\n",
       " 'if renal function normalizes (ie, creatinine',\n",
       " 'clearance > 60 ml/min or > 50 ml/min, according to local label/practice) and the patient continues',\n",
       " 'to tolerate this treatment, lenalidomide may then be escalated to 25 mg once daily.',\n",
       " 'patients may continue to receive treatment as outlined previously for 18 cycles (approximately',\n",
       " '18 months), or until progressive disease (pd) or unacceptable toxicity, whichever comes first.',\n",
       " 'after',\n",
       " '18 cycles, patients will continue treatment in the same randomization arm on the same schedule with',\n",
       " 'modified dose levels of the study drug and lendex:  reduce  (or placebo) dose to 3.0 mg,',\n",
       " 'reduce lenalidomide dose to 10 mg, and no dexamethasone.',\n",
       " 'the treatment period of the study is defined as any time a patient is receiving any of the study drug',\n",
       " 'regimen, and will be comprised of 28-day treatment cycles.',\n",
       " 'patients will be seen at regular treatment',\n",
       " 'cycle intervals while they are participating in the study:  weekly for the first 2 cycles, twice a',\n",
       " 'treatment cycle during the third cycle, and then once a treatment cycle for the remainder of their',\n",
       " 'participation in the treatment period, until they experience disease progression or discontinue for',\n",
       " 'alternate reasons.',\n",
       " 'if a patient discontinues treatment with the study regimen before disease',\n",
       " 'progression, they will enter the pfs follow-up period of the study.',\n",
       " 'patients will be assessed for disease response and progression by an independent review committee',\n",
       " '(irc).',\n",
       " 'response will be assessed according to the international myeloma working group (imwg)',\n",
       " 'criteria for all patients every cycle during the treatment period and subsequently every 4 weeks',\n",
       " 'during the pfs follow-up period until disease progression.',\n",
       " 'after disease progression, all patients',\n",
       " 'will be followed for survival in the overall survival (os) follow-up period.',\n",
       " 'patients will be',\n",
       " 'contacted every 12 weeks until death or termination of the study by the sponsor.',\n",
       " 'study population:',\n",
       " 'adult patients with a confirmed diagnosis of symptomatic mm, who have not received previous anti-',\n",
       " 'myeloma treatment, who are not transplant eligible, and who are candidates for treatment with',\n",
       " 'lendex will be enrolled in this study.',\n",
       " 'duration of study:',\n",
       " 'the duration of the study, including enrollment, treatment, and follow-up, will be approximately',\n",
       " '87 months, including a 27-month enrollment period and an additional 60-month (5-year) follow-up',\n",
       " 'from the last patient enrolled.',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'study overview diagram',\n",
       " 'a patients with a low creatinine clearance of \\uf0a3 60 ml/min (or \\uf0a3 50 ml/min, according to local label/practice)',\n",
       " 'will receive a reduced lenalidomide dose of 10 mg once daily on days 1 through 21 of a 28-day cycle.',\n",
       " 'the',\n",
       " 'lenalidomide dose may be escalated to 15 mg once daily after 2 cycles if the patient is not responding to',\n",
       " 'treatment and is tolerating the treatment.',\n",
       " 'if renal function normalizes (ie, creatinine clearance > 60 ml/min',\n",
       " 'or > 50 ml/min, according to local label/practice) and the patient continues to tolerate this treatment,',\n",
       " 'lenalidomide may then be escalated to 25 mg once daily.',\n",
       " 'b patients over 75 years of age at randomization will receive a reduced dexamethasone dose (20 mg).',\n",
       " 'c if the dose of  (or placebo) was reduced to 3.0 or 2.3 mg during the first 18 cycles of treatment,',\n",
       " 'dose will remain at that reduced level beyond 18 cycles(see table 4-1).',\n",
       " 'd if the dose of lenalidomide was reduced to 15 mg or 10 mg during the first 18 cycles of treatment, dose will',\n",
       " 'be 10 mg beyond 18 cycles.',\n",
       " 'if the lenalidomide dose was reduced to 5 mg during the first 18 cycles of',\n",
       " 'treatment, dose will remain at 5 mg beyond 18 cycles (see table 4-1).',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'schedule of events',\n",
       " 'treatment period',\n",
       " '28-day cycles',\n",
       " 'study procedures',\n",
       " 'g',\n",
       " 'n',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 'c',\n",
       " 's',\n",
       " 'cycle',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c3',\n",
       " 'c3',\n",
       " 'through',\n",
       " 'c4',\n",
       " 'c13',\n",
       " 'beyond',\n",
       " 'follow-up',\n",
       " 'pfs',\n",
       " 'os',\n",
       " 'every',\n",
       " '4 weeks',\n",
       " '± 1 wk',\n",
       " 'every',\n",
       " '12 weeks',\n",
       " '± 1 wk',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 't',\n",
       " 'f',\n",
       " 'n',\n",
       " 'e',\n",
       " '\\uf02b1 wk',\n",
       " 'days',\n",
       " 'window',\n",
       " 'informed consent',\n",
       " 'inclusion/exclusion criteriab',\n",
       " 'demographics',\n",
       " 'complete medical history',\n",
       " 'and disease staging',\n",
       " 'complete physical exam',\n",
       " 'symptom-directed physical',\n",
       " 'exam',\n",
       " 'ecog performance status',\n",
       " 'vital signs',\n",
       " 'height (cm)',\n",
       " 'weight (kg)',\n",
       " 'pregnancy testd',\n",
       " '12-lead ecg',\n",
       " 'hematology laboratorye',\n",
       " 'chemistry laboratorye',\n",
       " 'thyroid testing',\n",
       " 'urinalysis',\n",
       " 'eortc-qlq-c30 and',\n",
       " 'my-20g',\n",
       " 'eq-5dg',\n",
       " 'confidential',\n",
       " '-28 to -1',\n",
       " '± 2 days',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xc',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xf',\n",
       " 'xh',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xc',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xf',\n",
       " 'xh',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xi',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'study procedures',\n",
       " 'g',\n",
       " 'n',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 'c',\n",
       " 's',\n",
       " 'treatment period',\n",
       " '28-day cycles',\n",
       " 'cycle',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c3',\n",
       " 'c3',\n",
       " 'days',\n",
       " 'window',\n",
       " 'pain assessment: bpi-sf &',\n",
       " '24-hour analgesic form (also',\n",
       " 'for unscheduled visit)g',\n",
       " 'hu asssessment (also for',\n",
       " 'unscheduled visits)g',\n",
       " 'bone mineral density',\n",
       " '(dexa) scan',\n",
       " 'skeletal survey',\n",
       " 'radiographic disease',\n",
       " 'assessmentl',\n",
       " '\\uf0622-microglobulin',\n",
       " 'm-protein measurements',\n",
       " '(spep)',\n",
       " 'm-protein measurements',\n",
       " '(upep [24hr urine',\n",
       " 'collection])',\n",
       " 'serum free light chain',\n",
       " 'assay',\n",
       " 'immunofixation - serum and',\n",
       " 'urinen',\n",
       " 'quantification of igo',\n",
       " 'bone marrow aspiration',\n",
       " 'disease assessment',\n",
       " 'molecular analysis and',\n",
       " 'high-risk cytogenetic',\n",
       " 'confidential',\n",
       " '-28 to -1',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xm',\n",
       " 'xm',\n",
       " 'xm',\n",
       " 'xm',\n",
       " 'xm',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xp',\n",
       " 'xq',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xp',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xp',\n",
       " '± 2 days',\n",
       " 'through',\n",
       " 'c4',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xj',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'c13',\n",
       " 'beyond',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xj',\n",
       " 'xk',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xp',\n",
       " 'xp',\n",
       " 'follow-up',\n",
       " 'pfs',\n",
       " 'os',\n",
       " 'every',\n",
       " '4 weeks',\n",
       " '± 1 wk',\n",
       " 'every',\n",
       " '12 weeks',\n",
       " '± 1 wk',\n",
       " 'xi',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xj',\n",
       " 'xk',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xp',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 't',\n",
       " 'f',\n",
       " 'n',\n",
       " 'e',\n",
       " '\\uf02b1 wk',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xp',\n",
       " 'xq',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'study procedures',\n",
       " 'cycle',\n",
       " 'days',\n",
       " 'window',\n",
       " 'assessment',\n",
       " 'local cytogenetics',\n",
       " 'minimal residual',\n",
       " 'diseases',\n",
       " 'blood samples for biomarker',\n",
       " 'analysis',\n",
       " 'plasma biomarker',\n",
       " '(proteasome level)',\n",
       " 'blood sample for',\n",
       " 'germline dna',\n",
       " 'serum for bone',\n",
       " 'metabolism biomarkers',\n",
       " 'adverse event reporting',\n",
       " 'concomitant',\n",
       " 'medications/procedures',\n",
       " 'skeletal-related events',\n",
       " 'narcotic and other analgesic',\n",
       " 'use',\n",
       " 'new primary malignancy',\n",
       " 'assessment',\n",
       " 'survival',\n",
       " 'follow-up',\n",
       " 'pfs',\n",
       " 'os',\n",
       " 'every',\n",
       " '4 weeks',\n",
       " '± 1 wk',\n",
       " 'every',\n",
       " '12 weeks',\n",
       " '± 1 wk',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 't',\n",
       " 'f',\n",
       " 'n',\n",
       " 'e',\n",
       " '\\uf02b1 wk',\n",
       " 'g',\n",
       " 'n',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 'c',\n",
       " 's',\n",
       " 'treatment period',\n",
       " '28-day cycles',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c3',\n",
       " 'c3',\n",
       " 'through',\n",
       " 'c4',\n",
       " 'c13',\n",
       " 'beyond',\n",
       " '-28 to -1',\n",
       " '± 2 days',\n",
       " 'xr',\n",
       " 'x',\n",
       " 'x',\n",
       " 'xt',\n",
       " 'xt',\n",
       " 'xt',\n",
       " 'xt',\n",
       " 'recorded from the first dose of drug in the study drug regimen through 30 days after last dose of',\n",
       " 'drug in the study drug regimenu',\n",
       " 'serious adverse events and serious pretreatment events will be collected from signing of the',\n",
       " 'informed consent form through 30 days after the last dose of drug in the study drug regimen',\n",
       " 'recorded from the first dose of drug in the study drug regimen through 30 days after last dose of',\n",
       " 'drug in the study drug regimen',\n",
       " 'continuous from the start of study drug regimen administration until death or termination of the study by the sponsor',\n",
       " 'recorded from the first dose of study drug regimen until confirmed progressive disease',\n",
       " 'continuous from the start of study drug regimen administration until death or termination of the study by the sponsor',\n",
       " 'x',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'study procedures',\n",
       " 'cycle',\n",
       " 'days',\n",
       " 'window',\n",
       " 'g',\n",
       " 'n',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 'c',\n",
       " 's',\n",
       " 'treatment period',\n",
       " '28-day cycles',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c3',\n",
       " 'c3',\n",
       " 'through',\n",
       " 'c4',\n",
       " 'c13',\n",
       " 'beyond',\n",
       " '-28 to -1',\n",
       " '± 2 days',\n",
       " 'follow-up',\n",
       " 'pfs',\n",
       " 'os',\n",
       " 'every',\n",
       " '4 weeks',\n",
       " '± 1 wk',\n",
       " 'every',\n",
       " '12 weeks',\n",
       " '± 1 wk',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 't',\n",
       " 'f',\n",
       " 'n',\n",
       " 'e',\n",
       " '\\uf02b1 wk',\n",
       " '/placebo',\n",
       " 'lenalidomide',\n",
       " 'dexamethasone',\n",
       " 'abbreviations:  d = study day; del = deletion; ecog = eastern cooperative oncology group; os = overall survival; pfs = progression-free survival; spep = serum',\n",
       " 'continuous days 1-21 of each cycle',\n",
       " 'days 1, 8, 15, and 22 of each cycle',\n",
       " 'protein electrophoresis; t = translocation; upep = urine protein electrophoresis; wk = week;',\n",
       " 'study drug regimen administration',\n",
       " 'days 1, 8, and 15 of each cycle',\n",
       " 'tests and procedures should be performed on schedule, but occasional changes may be allowed (± 2 days) for holidays, vacations, and other administrative reasons.',\n",
       " 'if',\n",
       " 'the study schedule is shifted, both assessments and dosing must be shifted to ensure collection of assessments is completed prior to dosing.',\n",
       " 'if extenuating',\n",
       " 'circumstances prevent a patient from beginning treatment or completing a scheduled procedure or assessment within this time, the patient may continue the study',\n",
       " 'only with the permission of the mpi/designee clinician.',\n",
       " 'a quality review by mpi/designee clinician required prior to discontinuing patient from treatment for progressive disease.',\n",
       " 'b confirmation of patient eligibility by mpi/designee clinician required prior to randomization.',\n",
       " 'c weight to be taken day 1 of each cycle.',\n",
       " 'd pregnancy tests:',\n",
       " 'screening for all countries except canada:  females of childbearing potential (fcbp) are required to have two medically supervised negative pregnancy',\n",
       " 'tests (serum or urine with sensitivity of at least 25 miu/ml), even if continuous abstinence is the chosen method of contraception, prior to the first dose of',\n",
       " 'lenalidomide.',\n",
       " 'one test must be obtained within 10-14 days and the other test must be obtained within 24 hours prior to the start of the study drug regimen',\n",
       " 'at cycle 1, day 1.',\n",
       " 'screening for canada:  fcbp are required to have two medically supervised negative serum pregnancy tests with sensitivity of at least 25 miu/ml,',\n",
       " 'even if continuous abstinence is the chosen method of contraception, prior to the first dose of lenalidomide.',\n",
       " 'one test must be obtained within 7–14 days',\n",
       " 'and the other test within 24 hours prior to the start of the study drug regimen at cycle 1, day 1.',\n",
       " '\\uf0b7 on treatment:  pregnancy tests for fcbp to be collected weekly during cycle 1 and then within 24 hours of beginning each subsequent cycle.',\n",
       " 'lenalidomide package insert must be followed while patients remain on therapy.',\n",
       " 'if menstrual cycles are irregular, the pregnancy testing must occur',\n",
       " 'weekly for the first 28 days and then every 14 days while on therapy.',\n",
       " 'for canada: all pregnancy tests must be performed using serum with a sensitivity',\n",
       " 'of at least 25 miu/ml.',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'study procedures',\n",
       " 'cycle',\n",
       " 'days',\n",
       " 'window',\n",
       " 'g',\n",
       " 'n',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 'c',\n",
       " 's',\n",
       " 'treatment period',\n",
       " '28-day cycles',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c3',\n",
       " 'c3',\n",
       " 'through',\n",
       " 'c4',\n",
       " 'c13',\n",
       " 'beyond',\n",
       " '-28 to -1',\n",
       " '± 2 days',\n",
       " 'follow-up',\n",
       " 'pfs',\n",
       " 'os',\n",
       " 'every',\n",
       " '4 weeks',\n",
       " '± 1 wk',\n",
       " 'every',\n",
       " '12 weeks',\n",
       " '± 1 wk',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 't',\n",
       " 'f',\n",
       " 'n',\n",
       " 'e',\n",
       " '\\uf02b1 wk',\n",
       " 'end of treatment:  pregnancy for fcbp to be collected at treatment discontinuation and at day 28 following drug discontinuation (± 1 wk window for',\n",
       " 'other end of treatment assessments does not apply).',\n",
       " 'if menstrual cycles are irregular, the pregnancy testing must occur at drug discontinuation and at',\n",
       " 'days 14 and 28 following drug discontinuation.',\n",
       " 'for canada:  all pregnancy tests must be performed using serum with a sensitivity of at least 25 miu/ml.',\n",
       " 'e clinical laboratory evaluations will be performed by a central laboratory.',\n",
       " 'for dosing decisions, local hematology and chemistry laboratory results may be used;',\n",
       " 'however, samples must still be sent to central labs as well.',\n",
       " 'hematology and chemistry panels may be collected up to 3 days before day 1 dosing and 24 hours',\n",
       " 'before days 8, 15, and 22 dosing, where required.',\n",
       " 'local laboratory evaluations may be done more frequently at the investigators discretion, ie for acute',\n",
       " 'management of teaes.',\n",
       " 'f thyroid testing required every 4 cycles on treatment.',\n",
       " 'g patient-reported outcomes and hu assessment (ie, number of medical encounters) should be completed before any other study procedures are performed or study',\n",
       " 'drug regimen is administered.',\n",
       " 'h required every other cycle after cycle 2 (ie, cycles 1, 2, 4, 6, etc.)',\n",
       " 'during the treatment period.',\n",
       " 'i during the os follow-up, assessments can be made over the phone and do not require a clinic visit.',\n",
       " 'j dual-energy x-ray absorptiometry (dexa) scans will be done of the lumbar spine, femoral neck, and total body at screening, 6 months, 1 year, and then annually',\n",
       " 'until progressive disease.',\n",
       " 'k skeletal survey will be performed at screening (within 8 weeks prior to randomization) and a minimum of every 12 months until disease progression for all patients.',\n",
       " 'more frequent assessments can be done at the discretion of the investigator (ie, for suspected increased or new bone lesions).',\n",
       " 'l  patients with documented extramedullary disease must have radiographic disease assessments (ct/pet-ct/mri) performed at screening, every other cycle during',\n",
       " 'treatment, and every 8 weeks during the pfs follow-up period until disease progression.',\n",
       " 'modality should be kept consistent throughout.',\n",
       " 'screening evaluations may',\n",
       " 'be performed within 8 weeks prior to randomization.',\n",
       " 'm if the screening test was performed more than 14 days prior to the first dose, the test will be repeated at baseline.',\n",
       " 'n immunofixation to be done to confirm cr (undetectable m-protein by protein electrophoresis in both serum and urine will lead the central laboratory to perform',\n",
       " 'immunofixation testing in both serum and urine).',\n",
       " 'o blood samples for quantification of immunoglobulins (igm, igg, iga) will be obtained throughout the study at the time points specified.',\n",
       " 'quantitative igd and ige',\n",
       " 'will be done at screening (and baseline if needed) only.',\n",
       " 'for the rare patient with igd or ige multiple myeloma, the quantitative test for that antibody will be',\n",
       " 'followed at the same time points as quantitative igs (in addition to igm, igg, and iga).',\n",
       " 'p to be performed at local lab to assess disease status at baseline.',\n",
       " 'only to be repeated if patient is considered to possibly have resolution of serum and urine m-',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'study procedures',\n",
       " 'cycle',\n",
       " 'days',\n",
       " 'window',\n",
       " 'g',\n",
       " 'n',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 'c',\n",
       " 's',\n",
       " 'treatment period',\n",
       " '28-day cycles',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c1',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c2',\n",
       " 'c3',\n",
       " 'c3',\n",
       " 'through',\n",
       " 'c4',\n",
       " 'c13',\n",
       " 'beyond',\n",
       " '-28 to -1',\n",
       " '± 2 days',\n",
       " 'follow-up',\n",
       " 'pfs',\n",
       " 'os',\n",
       " 'every',\n",
       " '4 weeks',\n",
       " '± 1 wk',\n",
       " 'every',\n",
       " '12 weeks',\n",
       " '± 1 wk',\n",
       " 'n',\n",
       " 'e',\n",
       " 'e',\n",
       " 'r',\n",
       " 't',\n",
       " 'f',\n",
       " 'n',\n",
       " 'e',\n",
       " '\\uf02b1 wk',\n",
       " 'protein consistent with cr or to investigate suspected pd if applicable.',\n",
       " 'q bone marrow aspirate (first or second pull preferred) for molecular analysis and cytogenetics are required to be sent to the central lab at baseline.',\n",
       " 'an additional',\n",
       " 'bone marrow aspirate for patients who initially respond and then relapse is optional, but highly recommended.',\n",
       " 'r cytogenetics may also be done locally (optional) if the site has the capability to perform analysis and sufficient specimen available.',\n",
       " 'assessment of the following',\n",
       " 'should be obtained if possible:   +1q21, translocations t(4;14) and t(14;16), and del(17).',\n",
       " 's bone marrow aspirate collected when in cr.',\n",
       " 'samples are required to be sent to central lab for analysis.',\n",
       " 't bone metabolism biomarkers, including ictp, balp, srankl/opg, and dkk-1, will be collected at screening, and predose every cycle from cycle 1 through',\n",
       " 'cycle 6.',\n",
       " 'last sampling will be collected predose after 1 year from the first dose.',\n",
       " 'each sample will be collected during the laboratory assessment before study drug',\n",
       " 'regimen administration.',\n",
       " 'u when peripheral neuropathy occurs, each subsequent monthly evaluation will record the grade of peripheral neuropathy at that visit.',\n",
       " '(this is in contrast to other',\n",
       " 'ae’s where only increases in grade are recorded until the maximum grade is reached and then followed at that grade until complete resolution or return to baseline.)',\n",
       " 'peripheral neuropathy will be followed monthly until 1) resolution of peripheral neuropathy, 2) the start of a second-line alternative antineoplastic treatment, or 3) 6',\n",
       " 'months after progression has occurred, whichever occurs first.',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " ' pharmacokinetic sampling schedule',\n",
       " 'cycle 1',\n",
       " 'day 1',\n",
       " '1 hour (\\uf0b1 0.25)',\n",
       " '4 hour (\\uf0b1 0.75)',\n",
       " 'x',\n",
       " 'x',\n",
       " 'day 14',\n",
       " 'predoseb',\n",
       " 'x',\n",
       " 'cycle 2-3',\n",
       " 'day 1',\n",
       " 'predosea',\n",
       " 'x',\n",
       " 'day 14',\n",
       " 'predoseb',\n",
       " 'x',\n",
       " 'cycles 4-12',\n",
       " 'day 1',\n",
       " 'predosea',\n",
       " 'x',\n",
       " 'a day 1 predose pk assessments should occur within 2 hours of dosing.',\n",
       " 'b if pk sample is taken on a dosing day (due to allowable \\uf0b1 2-day window of visits), pk sample must be taken within 2 hours prior to dose of any',\n",
       " 'study drug.',\n",
       " 'if pk sample is taken on a non-dosing day, ie sample on day 14 and dose on day 15, pk sample can be taken at any time during the',\n",
       " 'visit.',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " 'table of contents',\n",
       " 'list of tables..................................................................................................................16',\n",
       " 'list of figures ................................................................................................................17',\n",
       " 'list of abbreviations and glossary of terms ............................................17',\n",
       " 'study period definitions..........................................................................................22',\n",
       " 'background and study rationale ................................................................23',\n",
       " '1.1 scientific background ..................................................................................................23',\n",
       " '1.1.1 disease under treatment.......................................................................................23',\n",
       " '1.1.2 , millennium’s next-generation proteasome inhibitor ........................24',\n",
       " '1.2 nonclinical experience.................................................................................................25',\n",
       " '1.3 clinical experience.......................................................................................................25',\n",
       " '1.3.1 clinical trial experience using the iv formulation of  ......................25',\n",
       " '1.3.2 clinical trial experience using the oral formulation of  ...................26',\n",
       " '1.4 pharmacokinetics and drug metabolism......................................................................27',\n",
       " '1.5 study rationale.............................................................................................................28',\n",
       " '1.6 rationale for the combination of , lenalidomide, and dexamethasone.....29',\n",
       " '1.6.1 combination of , lenalidomide, and dexamethasone..........................29',\n",
       " '1.6.2 rationale for , lenalidomide, and dexamethasone dose and',\n",
       " 'schedule selection..........................................................................................31',\n",
       " '1.6.3 rationale for the molecular analyses ...................................................................33',\n",
       " '1.6.4 rationale for the combination of , lenalidomide, and',\n",
       " 'dexamethasone in patients with high-risk cytogenetic characteristics ......34',\n",
       " '1.6.5 minimal residual disease assessment .................................................................35',\n",
       " '1.6.6 rationale for bone disease assessment................................................................36',\n",
       " '1.7 potential risks and benefits.........................................................................................36',\n",
       " 'study objectives ......................................................................................................37',\n",
       " '2.1 primary objectives .......................................................................................................37',\n",
       " '2.2 secondary objectives ...................................................................................................37',\n",
       " '2.3 exploratory objectives.................................................................................................38',\n",
       " 'study endpoints........................................................................................................39',\n",
       " '3.1 primary endpoint..........................................................................................................39',\n",
       " '3.2 secondary endpoints ....................................................................................................39',\n",
       " '3.3 exploratory endpoints..................................................................................................40',\n",
       " 'study design ...............................................................................................................41',\n",
       " '4.1 overview of study design ...........................................................................................41',\n",
       " '4.2 number of patients .......................................................................................................44',\n",
       " '4.3 duration of study .........................................................................................................45',\n",
       " 'study population.....................................................................................................45',\n",
       " '5.1 inclusion criteria ..........................................................................................................45',\n",
       " '5.2 exclusion criteria.........................................................................................................48',\n",
       " 'study drug...................................................................................................................50',\n",
       " '6.1 test article () and matched placebo ...........................................................50',\n",
       " '6.2 background therapies..................................................................................................51',\n",
       " '6.2.1 lenalidomide administration................................................................................51',\n",
       " '6.2.2 dexamethasone administration.............................................................................52',\n",
       " 'confidential',\n",
       " ',  eudract:  2013-000326-54',\n",
       " '6.3 dose-modification guidelines .....................................................................................52',\n",
       " '6.4 criteria for dose modification (delays, reductions, and discontinuations)...............53',\n",
       " '6.4.1 dose adjustments for hematologic and nonhematologic toxicity:  study',\n",
       " 'drug and lenalidomide ..................................................................................53',\n",
       " '6.4.2 study drug treatment modification......................................................................56',\n",
       " '6.4.3 lenalidomide treatment modification..................................................................58',\n",
       " '6.4.4 dexamethasone-related treatment modification.................................................59',\n",
       " '6.5 criteria for toxicity recovery before beginning the next cycle of treatment .........60',\n",
       " '6.6 excluded concomitant medications and procedures ...................................................60',\n",
       " '6.7 permitted concomitant medications and procedures...................................................61',\n",
       " '6.8 precautions and restrictions.........................................................................................62',\n",
       " '6.9 contraception requirements ........................................................................................62',\n",
       " '6.10 management of clinical events .................................................................................65',\n",
       " '6.11 blinding and unblinding ............................................................................................68',\n",
       " '6.12 description of investigational agents ........................................................................68',\n",
       " '6.13 preparation, reconstitution, and dispensing..............................................................69',\n",
       " '6.14 packaging and labeling..............................................................................................69',\n",
       " '6.15 storage, handling, and accountability.......................................................................69',\n",
       " '6.15.1 background therapies .........................................................................................70',\n",
       " '6.16 other protocol-specified materials ............................................................................71',\n",
       " 'study conduct...........................................................................................................71',\n",
       " '7.1 study personnel and organizations..............................................................................71',\n",
       " '7.2 arrangements for recruitment of patients ...................................................................72',\n",
       " '7.3 treatment group assignments.....................................................................................72',\n",
       " '7.4 study procedures ..........................................................................................................72',\n",
       " '7.4.1 informed consent ..................................................................................................72',\n",
       " '7.4.2 patient demographics............................................................................................72',\n",
       " '7.4.3 medical history .....................................................................................................73',\n",
       " '7.4.4 physical examination ............................................................................................73',\n",
       " '7.4.5 vital signs..............................................................................................................73',\n",
       " '7.4.6 eastern cooperative oncology group performance status...................................73',\n",
       " '7.4.7 pregnancy test.......................................................................................................73',\n",
       " '7.4.8 concomitant medications and procedures ............................................................74',\n",
       " '7.4.9 adverse events ......................................................................................................74',\n",
       " '7.4.10 enrollment ...........................................................................................................75',\n",
       " '7.4.11 electrocardiogram................................................................................................75',\n",
       " '7.4.12 clinical laboratory evaluations ..........................................................................75',\n",
       " '7.4.13 health utilization data collection ......................................................................76',\n",
       " '7.4.14 quality of life assessment (european organization for research and',\n",
       " 'treatment of cancer)......................................................................................76',\n",
       " '7.4.15 pain assessment ..................................................................................................77',\n",
       " '7.4.16 utility measurement ............................................................................................78',\n",
       " '7.4.17 skeletal survey ....................................................................................................78',\n",
       " '7.4.18 skeletal-related events .......................................................................................79',\n",
       " '7.4.19 bone mineral density..........................................................................................79',\n",
       " '7.4.20 radiographic disease assessments.....................................................................79',\n",
       " 'confidential',\n",
       " ', eudract:  2013-000326-54',\n",
       " '7.4.21 \\uf0622-microglobulin.................................................................................................79',\n",
       " '7.4.22 quantification of m-protein.................................................................................79',\n",
       " '7.4.23 quantification of immunoglobulin (ig) ...............................................................79',\n",
       " '7.4.24 serum free light chain assay............................................................................80',\n",
       " '7.4.25 immunofixation of serum and urine...................................................................80',\n",
       " '7.4.26 bone marrow evaluation.....................................................................................80',\n",
       " '7.4.27 response assessment ..........................................................................................81',\n",
       " '7.4.28 pharmacokinetic measurements ..........................................................................82',\n",
       " '7.4.29 blood sample for biomarker analysis................................................................82',\n",
       " '7.4.30 treatment beyond 18 cycles...............................................................................83',\n",
       " '7.4.31 follow-up assessments (pfs and os) ................................................................83',\n",
       " '7.5 unscheduled visits.......................................................................................................84',\n",
       " '7.6 study compliance.........................................................................................................84',\n",
       " '7.7 completion of treatment..............................................................................................84',\n",
       " '7.8 completion of study.....................................................................................................85',\n",
       " '7.9 discontinuation of treatment with the study drug regimen, and patient',\n",
       " 'replacement .........................................................................................................85',\n",
       " '7.10 withdrawal of patients from study ...........................................................................85',\n",
       " 'statistical and quantitative analyses.....................................................86',\n",
       " '8.1 statistical methods .......................................................................................................86',\n",
       " '8.1.1 determination of sample size...............................................................................86',\n",
       " '8.1.2 randomization and stratification ..........................................................................87',\n",
       " '8.1.3 populations for analysis........................................................................................87',\n",
       " '8.1.4 procedures for handling missing, unused, and spurious data ............................88',\n",
       " '8.1.5 demographic and baseline characteristics ...........................................................89',\n",
       " '8.1.6 efficacy analysis...................................................................................................89',\n",
       " '8.1.7 analyses of patient-reported outcomes and health economics..........................92',\n",
       " '8.1.8 pharmacokinetics and biomarkers.........................................................................94',\n",
       " '8.1.9 safety analysis ......................................................................................................95',\n",
       " '8.1.10 interim analysis...................................................................................................98',\n",
       " 'study committees....................................................................................................98',\n",
       " '9.1 steering committee ......................................................................................................98',\n",
       " '9.2 independent review committee ..................................................................................99',\n",
       " '9.3 independent data monitoring committee....................................................................99',\n",
       " 'adverse events......................................................................................................100',\n",
       " '10.1 definitions ................................................................................................................100',\n",
       " '10.1.1 pretreatment event definition ...........................................................................100',\n",
       " '10.1.2 adverse event definition ..................................................................................100',\n",
       " '10.1.3 serious adverse event definition .....................................................................100',\n",
       " '10.2 procedures for recording and reporting adverse events and serious',\n",
       " 'adverse events ...................................................................................................101',\n",
       " '10.3 monitoring of adverse events and period of observation ......................................103',\n",
       " '10.4 procedures for reporting drug exposure during pregnancy and birth events ......103',\n",
       " 'administrative requirements ......................................................................104',\n",
       " '11.1 good clinical practice..............................................................................................104',\n",
       " '11.2 data quality assurance............................................................................................104',\n",
       " 'confidential',\n",
       " ',  eudract:  2013-000326-54',\n",
       " '11.3 electronic case report form completion................................................................104',\n",
       " ...]"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lst[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "seq1 = lst[0]\n",
    "seq2 = lst[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "size = 1\n",
    "var01 = [seq1[i:i+size] for i  in range(0, len(seq1), size)]\n",
    "var02 = [seq2[i:i+size] for i  in range(0, len(seq2), size)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim import corpora, models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "dictionary = corpora.Dictionary(var01)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "corpus = [dictionary.doc2bow(text) for text in var01]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(0, 1)]"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "corpus[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "#np.random.seed(1) # setting random seed to get the same results each time."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Applying the LDA model\n",
    "corpus is a document-term matrix and now we’re ready to generate an LDA model:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [],
   "source": [
    "np.random.seed(1) # setting random seed to get the same results each time.\n",
    "ldamodel = models.ldamodel.LdaModel(corpus, num_topics=6, id2word = dictionary, passes=20)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Parameters:\n",
    "* num_topics: required. An LDA model requires the user to determine how many topics should be generated. Our document set is small, so we’re only asking for three topics.\n",
    "* id2word: required. The LdaModel class requires our previous dictionary to map ids to strings.\n",
    "* passes: optional. The number of laps the model will take through corpus. The greater the number of passes, the more accurate the model will be. A lot of passes can be slow on a very large corpus.\n",
    "\n",
    "#### Examining the results\n",
    "* Our LDA model is now stored as ldamodel. We can review our topics with the print_topic and print_topics methods:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[(0, '0.035*\"of measured myeloma cell mass with presenting clinical features, response to\" + 0.035*\"treatment, and survival.\" + 0.035*\"server date\" + 0.035*\"c16014 clinical protocol\" + 0.035*\"oncology:  adult cancer pain, v.1.2010; 2010.\"'), (1, '0.042*\"confidential\" + 0.035*\"signed by\" + 0.035*\"world health organization.\" + 0.035*\"new england journal of medicine\" + 0.035*\"(dd-mmm-yyyy hh:mm)\"'), (2, '0.012*\"interrupt treatment\" + 0.005*\"level\" + 0.004*\"within the same cycle\" + 0.004*\"± 1 wk\" + 0.004*\"c3\"'), (3, '0.106*\", eudract:  2013-000326-54\" + 0.008*\"c1\" + 0.005*\"the\" + 0.004*\"resume and maintain\" + 0.003*\"dexamethasone\"'), (4, '0.038*\"national comprehensive cancer network.\" + 0.037*\"a clinical staging system for multiple myeloma.\" + 0.037*\"the treatment of cancer pain.\" + 0.009*\"e\" + 0.003*\"every\"'), (5, '0.037*\"x\" + 0.033*\"nccn clinical practice guidelines in\" + 0.033*\"foley km.\" + 0.033*\"cancer pain relief.\" + 0.003*\"(mg/d)\"')]\n"
     ]
    }
   ],
   "source": [
    "print(ldamodel.print_topics(num_topics=6, num_words=5))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [],
   "source": [
    "words = ldamodel.print_topics(num_topics=6, num_words=5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(0,\n",
       "  '0.035*\"of measured myeloma cell mass with presenting clinical features, response to\" + 0.035*\"treatment, and survival.\" + 0.035*\"server date\" + 0.035*\"c16014 clinical protocol\" + 0.035*\"oncology:  adult cancer pain, v.1.2010; 2010.\"'),\n",
       " (1,\n",
       "  '0.042*\"confidential\" + 0.035*\"signed by\" + 0.035*\"world health organization.\" + 0.035*\"new england journal of medicine\" + 0.035*\"(dd-mmm-yyyy hh:mm)\"'),\n",
       " (2,\n",
       "  '0.012*\"interrupt treatment\" + 0.005*\"level\" + 0.004*\"within the same cycle\" + 0.004*\"± 1 wk\" + 0.004*\"c3\"'),\n",
       " (3,\n",
       "  '0.106*\", eudract:  2013-000326-54\" + 0.008*\"c1\" + 0.005*\"the\" + 0.004*\"resume and maintain\" + 0.003*\"dexamethasone\"'),\n",
       " (4,\n",
       "  '0.038*\"national comprehensive cancer network.\" + 0.037*\"a clinical staging system for multiple myeloma.\" + 0.037*\"the treatment of cancer pain.\" + 0.009*\"e\" + 0.003*\"every\"'),\n",
       " (5,\n",
       "  '0.037*\"x\" + 0.033*\"nccn clinical practice guidelines in\" + 0.033*\"foley km.\" + 0.033*\"cancer pain relief.\" + 0.003*\"(mg/d)\"')]"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "words"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "seq1 = lst[0]\n",
    "seq2 = lst[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "size = 1\n",
    "var01 = [seq1[i:i+size] for i  in range(0, len(seq1), size)]\n",
    "var02 = [seq2[i:i+size] for i  in range(0, len(seq2), size)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['mln9708'],\n",
       " ['clinical'],\n",
       " ['study'],\n",
       " ['protocol'],\n",
       " ['c16014'],\n",
       " ['eudract'],\n",
       " ['clinical'],\n",
       " ['study'],\n",
       " ['protocol'],\n",
       " ['c16014'],\n",
       " ['a'],\n",
       " ['phase'],\n",
       " ['randomized'],\n",
       " ['double-blind'],\n",
       " ['multicenter'],\n",
       " ['study'],\n",
       " ['comparing'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['plus'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['versus'],\n",
       " ['placebo'],\n",
       " ['plus'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['adult'],\n",
       " ['patients'],\n",
       " ['with'],\n",
       " ['newly'],\n",
       " ['diagnosed'],\n",
       " ['multiple'],\n",
       " ['myeloma'],\n",
       " ['mln9708'],\n",
       " ['protocol'],\n",
       " ['number'],\n",
       " ['indication'],\n",
       " ['phase'],\n",
       " ['sponsor'],\n",
       " ['eudract'],\n",
       " ['number'],\n",
       " ['therapeutic'],\n",
       " ['area'],\n",
       " ['protocol'],\n",
       " ['history'],\n",
       " ['original'],\n",
       " ['approved'],\n",
       " ['c16014'],\n",
       " ['newly'],\n",
       " ['diagnosed'],\n",
       " ['multiple'],\n",
       " ['myeloma'],\n",
       " ['millennium'],\n",
       " ['pharmaceuticals'],\n",
       " ['inc'],\n",
       " ['oncology'],\n",
       " ['february'],\n",
       " ['millennium'],\n",
       " ['pharmaceuticals'],\n",
       " ['inc'],\n",
       " ['landsdowne'],\n",
       " ['street'],\n",
       " ['cambridge'],\n",
       " ['ma'],\n",
       " ['usa'],\n",
       " ['telephone'],\n",
       " ['note'],\n",
       " ['if'],\n",
       " ['document'],\n",
       " ['approved'],\n",
       " ['electronically'],\n",
       " ['electronic'],\n",
       " ['approval'],\n",
       " ['signatures'],\n",
       " ['may'],\n",
       " ['found'],\n",
       " ['end'],\n",
       " ['document'],\n",
       " ['dixie-lee'],\n",
       " ['esseltine'],\n",
       " ['md'],\n",
       " ['vice'],\n",
       " ['president'],\n",
       " ['oncology'],\n",
       " ['clinical'],\n",
       " ['research'],\n",
       " ['designee'],\n",
       " ['signature'],\n",
       " ['date'],\n",
       " ['dd'],\n",
       " ['month'],\n",
       " ['yyyy'],\n",
       " ['ai-min'],\n",
       " ['hui'],\n",
       " ['md'],\n",
       " ['phd'],\n",
       " ['global'],\n",
       " ['clinical'],\n",
       " ['lead'],\n",
       " ['designee'],\n",
       " ['signature'],\n",
       " ['date'],\n",
       " ['dd'],\n",
       " ['month'],\n",
       " ['yyyy'],\n",
       " ['confidentiality'],\n",
       " ['statement'],\n",
       " ['the'],\n",
       " ['information'],\n",
       " ['contained'],\n",
       " ['herein'],\n",
       " ['confidential'],\n",
       " ['proprietary'],\n",
       " ['property'],\n",
       " ['millennium'],\n",
       " ['pharmaceuticals'],\n",
       " ['unauthorized'],\n",
       " ['use'],\n",
       " ['disclosure'],\n",
       " ['information'],\n",
       " ['without'],\n",
       " ['prior'],\n",
       " ['written'],\n",
       " ['authorization'],\n",
       " ['millennium'],\n",
       " ['pharmaceuticals'],\n",
       " ['expressly'],\n",
       " ['prohibited'],\n",
       " ['confidential'],\n",
       " ['mln9708'],\n",
       " ['clinical'],\n",
       " ['study'],\n",
       " ['protocol'],\n",
       " ['c16014'],\n",
       " ['eudract'],\n",
       " ['protocol'],\n",
       " ['summary'],\n",
       " ['study'],\n",
       " ['title'],\n",
       " ['a'],\n",
       " ['phase'],\n",
       " ['randomized'],\n",
       " ['double-blind'],\n",
       " ['multicenter'],\n",
       " ['study'],\n",
       " ['comparing'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['plus'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['versus'],\n",
       " ['placebo'],\n",
       " ['plus'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['adult'],\n",
       " ['patients'],\n",
       " ['with'],\n",
       " ['newly'],\n",
       " ['diagnosed'],\n",
       " ['multiple'],\n",
       " ['myeloma'],\n",
       " ['study'],\n",
       " ['phase'],\n",
       " ['number'],\n",
       " ['patients'],\n",
       " ['approximately'],\n",
       " ['study'],\n",
       " ['objectives'],\n",
       " ['primary'],\n",
       " ['objective'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['whether'],\n",
       " ['addition'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['improves'],\n",
       " ['progression-free'],\n",
       " ['survival'],\n",
       " ['pfs'],\n",
       " ['patients'],\n",
       " ['newly-diagnosed'],\n",
       " ['multiple'],\n",
       " ['myeloma'],\n",
       " ['ndmm'],\n",
       " ['key'],\n",
       " ['secondary'],\n",
       " ['objectives'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['whether'],\n",
       " ['addition'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['improves'],\n",
       " ['rate'],\n",
       " ['complete'],\n",
       " ['response'],\n",
       " ['cr'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['whether'],\n",
       " ['addition'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['improves'],\n",
       " ['overall'],\n",
       " ['survival'],\n",
       " ['os'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['whether'],\n",
       " ['addition'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['improves'],\n",
       " ['pain'],\n",
       " ['response'],\n",
       " ['rate'],\n",
       " ['assessed'],\n",
       " ['brief'],\n",
       " ['pain'],\n",
       " ['inventory'],\n",
       " ['short'],\n",
       " ['form'],\n",
       " ['bpi-sf'],\n",
       " ['analgesic'],\n",
       " ['use'],\n",
       " ['other'],\n",
       " ['secondary'],\n",
       " ['objectives'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['overall'],\n",
       " ['response'],\n",
       " ['rate'],\n",
       " ['orr'],\n",
       " ['including'],\n",
       " ['partial'],\n",
       " ['response'],\n",
       " ['pr'],\n",
       " ['good'],\n",
       " ['partial'],\n",
       " ['response'],\n",
       " ['vgpr'],\n",
       " ['cr'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['time'],\n",
       " ['response'],\n",
       " ['ttr'],\n",
       " ['duration'],\n",
       " ['response'],\n",
       " ['dor'],\n",
       " ['time'],\n",
       " ['progression'],\n",
       " ['ttp'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['safety'],\n",
       " ['addition'],\n",
       " ['mln9708'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['to'],\n",
       " ['assess'],\n",
       " ['change'],\n",
       " ['global'],\n",
       " ['health'],\n",
       " ['status'],\n",
       " ['measured'],\n",
       " ['global'],\n",
       " ['health'],\n",
       " ['status'],\n",
       " ['functioning'],\n",
       " ['symptoms'],\n",
       " ['measured'],\n",
       " ['patient-reported'],\n",
       " ['outcome'],\n",
       " ['pro'],\n",
       " ['instrument'],\n",
       " ['european'],\n",
       " ['organization'],\n",
       " ['research'],\n",
       " ['treatment'],\n",
       " ['cancer'],\n",
       " ['quality'],\n",
       " ['life'],\n",
       " ['questionnaire'],\n",
       " ['eortc'],\n",
       " ['qlq-c30'],\n",
       " ['my-20'],\n",
       " ['module'],\n",
       " ['to'],\n",
       " ['determine'],\n",
       " ['pfs'],\n",
       " ['os'],\n",
       " ['high-risk'],\n",
       " ['cytogenetic'],\n",
       " ['patient'],\n",
       " ['groups'],\n",
       " ['defined'],\n",
       " ['following'],\n",
       " ['cytogenetic'],\n",
       " ['abnormalities'],\n",
       " ['+1q'],\n",
       " ['del'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['relationship'],\n",
       " ['polymorphisms'],\n",
       " ['proteasome'],\n",
       " ['nfkb-related'],\n",
       " ['genes'],\n",
       " ['psmb1'],\n",
       " ['traf-3'],\n",
       " ['circulating'],\n",
       " ['proteasome'],\n",
       " ['levels'],\n",
       " ['response'],\n",
       " ['dor'],\n",
       " ['pfs'],\n",
       " ['using'],\n",
       " ['blood'],\n",
       " ['samples'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['frequency'],\n",
       " ['detection'],\n",
       " ['minimal'],\n",
       " ['residual'],\n",
       " ['disease'],\n",
       " ['via'],\n",
       " ['flow'],\n",
       " ['cytometry'],\n",
       " ['patients'],\n",
       " ['assessed'],\n",
       " ['cr'],\n",
       " ['impact'],\n",
       " ['pfs'],\n",
       " ['os'],\n",
       " ['to'],\n",
       " ['assess'],\n",
       " ['time'],\n",
       " ['pain'],\n",
       " ['progression'],\n",
       " ['confidential'],\n",
       " ['mln9708'],\n",
       " ['clinical'],\n",
       " ['study'],\n",
       " ['protocol'],\n",
       " ['c16014'],\n",
       " ['eudract'],\n",
       " ['to'],\n",
       " ['collect'],\n",
       " ['pharmacokinetic'],\n",
       " ['pk'],\n",
       " ['data'],\n",
       " ['contribute'],\n",
       " ['population'],\n",
       " ['pk'],\n",
       " ['analyses'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['frequency'],\n",
       " ['skeletal-related'],\n",
       " ['events'],\n",
       " ['eg'],\n",
       " ['new'],\n",
       " ['fractures'],\n",
       " ['excluding'],\n",
       " ['vertebral'],\n",
       " ['compression'],\n",
       " ['rib'],\n",
       " ['fractures'],\n",
       " ['irradiation'],\n",
       " ['surgery'],\n",
       " ['bone'],\n",
       " ['spinal'],\n",
       " ['cord'],\n",
       " ['compression'],\n",
       " ['baseline'],\n",
       " ['last'],\n",
       " ['survival'],\n",
       " ['assessment'],\n",
       " ['exploratory'],\n",
       " ['objectives'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['health'],\n",
       " ['utilization'],\n",
       " ['hu'],\n",
       " ['collect'],\n",
       " ['euroqol'],\n",
       " ['5-dimensional'],\n",
       " ['health'],\n",
       " ['questionnaire'],\n",
       " ['eq-5d'],\n",
       " ['to'],\n",
       " ['assess'],\n",
       " ['time'],\n",
       " ['pain'],\n",
       " ['response'],\n",
       " ['duration'],\n",
       " ['pain'],\n",
       " ['response'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['potential'],\n",
       " ['relationship'],\n",
       " ['response/'],\n",
       " ['resistance'],\n",
       " ['patient'],\n",
       " ['outcome'],\n",
       " ['mln9708'],\n",
       " ['treatment'],\n",
       " ['mutations'],\n",
       " ['key'],\n",
       " ['signaling'],\n",
       " ['pathways'],\n",
       " ['determined'],\n",
       " ['clinically'],\n",
       " ['meaningful'],\n",
       " ['ras/raf'],\n",
       " ['using'],\n",
       " ['bone'],\n",
       " ['marrow'],\n",
       " ['aspirates'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['potential'],\n",
       " ['relationship'],\n",
       " ['response/'],\n",
       " ['resistance'],\n",
       " ['patient'],\n",
       " ['outcome'],\n",
       " ['mln9708'],\n",
       " ['treatment'],\n",
       " ['tumor'],\n",
       " ['gene'],\n",
       " ['expression'],\n",
       " ['patterns'],\n",
       " ['including'],\n",
       " ['nfkb'],\n",
       " ['protein'],\n",
       " ['synthesis'],\n",
       " ['signatures'],\n",
       " ['well'],\n",
       " ['pathway'],\n",
       " ['signatures'],\n",
       " ['transcript'],\n",
       " ['levels'],\n",
       " ['determined'],\n",
       " ['clinically'],\n",
       " ['meaningful'],\n",
       " ['using'],\n",
       " ['bone'],\n",
       " ['marrow'],\n",
       " ['aspirates'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['potential'],\n",
       " ['mechanisms'],\n",
       " ['treatment-emergent'],\n",
       " ['resistance'],\n",
       " ['somatic'],\n",
       " ['mutations'],\n",
       " ['proteasome'],\n",
       " ['subunits'],\n",
       " ['key'],\n",
       " ['signaling'],\n",
       " ['pathways'],\n",
       " ['change'],\n",
       " ['pathways'],\n",
       " ['activity'],\n",
       " ['tumors'],\n",
       " ['initially'],\n",
       " ['respond'],\n",
       " ['therapy'],\n",
       " ['exhibit'],\n",
       " ['progressive'],\n",
       " ['disease'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['effects'],\n",
       " ['mln9708'],\n",
       " ['therapy'],\n",
       " ['changes'],\n",
       " ['bone'],\n",
       " ['mineral'],\n",
       " ['density'],\n",
       " ['assessed'],\n",
       " ['dual-energy'],\n",
       " ['x-ray'],\n",
       " ['absorptiometry'],\n",
       " ['dexa'],\n",
       " ['changes'],\n",
       " ['bone'],\n",
       " ['metabolism'],\n",
       " ['biomarkers'],\n",
       " ['srankl/opg'],\n",
       " ['dkk-1'],\n",
       " ['levels'],\n",
       " ['using'],\n",
       " ['blood'],\n",
       " ['samples'],\n",
       " ['to'],\n",
       " ['evaluate'],\n",
       " ['resolution'],\n",
       " ['improvement'],\n",
       " ['peripheral'],\n",
       " ['neuropathy'],\n",
       " ['pn'],\n",
       " ['occurs'],\n",
       " ['grading'],\n",
       " ['subsequent'],\n",
       " ['monthly'],\n",
       " ['visit'],\n",
       " ['resolution'],\n",
       " ['peripheral'],\n",
       " ['neuropathy'],\n",
       " ['start'],\n",
       " ['alternative'],\n",
       " ['antineoplastic'],\n",
       " ['treatment'],\n",
       " ['months'],\n",
       " ['progression'],\n",
       " ['occurred'],\n",
       " ['whichever'],\n",
       " ['comes'],\n",
       " ['first'],\n",
       " ['overview'],\n",
       " ['study'],\n",
       " ['design'],\n",
       " ['this'],\n",
       " ['phase'],\n",
       " ['randomized'],\n",
       " ['double-blind'],\n",
       " ['multicenter'],\n",
       " ['study'],\n",
       " ['evaluate'],\n",
       " ['safety'],\n",
       " ['efficacy'],\n",
       " ['mln9708'],\n",
       " ['versus'],\n",
       " ['placebo'],\n",
       " ['added'],\n",
       " ['lenalidomide'],\n",
       " ['dexamethasone'],\n",
       " ['lendex'],\n",
       " ['patients'],\n",
       " ['ndmm'],\n",
       " ['adult'],\n",
       " ['patients'],\n",
       " ['confirmed'],\n",
       " ['diagnosis'],\n",
       " ['symptomatic'],\n",
       " ['multiple'],\n",
       " ['myeloma'],\n",
       " ['mm'],\n",
       " ['received'],\n",
       " ['previous'],\n",
       " ['anti-myeloma'],\n",
       " ['treatment'],\n",
       " ['ineligible'],\n",
       " ['high-dose'],\n",
       " ['therapy'],\n",
       " ['plus'],\n",
       " ['stem'],\n",
       " ['cell'],\n",
       " ['transplantation'],\n",
       " ['hdt-sct'],\n",
       " ['age'],\n",
       " ['ie'],\n",
       " ['years'],\n",
       " ['coexisting'],\n",
       " ['conditions'],\n",
       " ['per'],\n",
       " ['investigator'],\n",
       " ['judgment'],\n",
       " ['candidates'],\n",
       " ['treatment'],\n",
       " ['lendex'],\n",
       " ['standard'],\n",
       " ['therapy'],\n",
       " ['meet'],\n",
       " ['eligibility'],\n",
       " ['criteria'],\n",
       " ['detailed'],\n",
       " ['section'],\n",
       " ['enrolled'],\n",
       " ['study'],\n",
       " ['following'],\n",
       " ['screening'],\n",
       " ['period'],\n",
       " ['patients'],\n",
       " ['enrolled'],\n",
       " ['randomized'],\n",
       " ['receive'],\n",
       " ['either'],\n",
       " ['mln9708'],\n",
       " ['placebo'],\n",
       " ['double-blind'],\n",
       " ['fashion'],\n",
       " ['addition'],\n",
       " ['background'],\n",
       " ['therapy'],\n",
       " ['lendex'],\n",
       " ['eligible'],\n",
       " ['patients'],\n",
       " ['randomized'],\n",
       " ['ratio'],\n",
       " ['treatment'],\n",
       " ['arms'],\n",
       " ['stratified'],\n",
       " ['age'],\n",
       " ['years'],\n",
       " ['vs'],\n",
       " ['international'],\n",
       " ['staging'],\n",
       " ['system'],\n",
       " ['iss'],\n",
       " ['stage'],\n",
       " ['vs'],\n",
       " ['stage'],\n",
       " ['bpi-sf'],\n",
       " ['worst'],\n",
       " ['pain'],\n",
       " ['score'],\n",
       " ['vs'],\n",
       " ['screening'],\n",
       " ['patients'],\n",
       " ['receive'],\n",
       " ['oral'],\n",
       " ['mln9708'],\n",
       " ['mg'],\n",
       " ['matching'],\n",
       " ['placebo'],\n",
       " ['capsule'],\n",
       " ['days'],\n",
       " ['plus'],\n",
       " ['lenalidomide'],\n",
       " ['mg'],\n",
       " ['days'],\n",
       " ['dexamethasone'],\n",
       " ['mg'],\n",
       " ['days'],\n",
       " ['28-day'],\n",
       " ['cycle'],\n",
       " ['patients'],\n",
       " ['years'],\n",
       " ['age'],\n",
       " ['receive'],\n",
       " ['reduced'],\n",
       " ['dexamethasone'],\n",
       " ['dose'],\n",
       " ['mg'],\n",
       " ['confidential'],\n",
       " ['mln9708'],\n",
       " ['clinical'],\n",
       " ['study'],\n",
       " ['protocol'],\n",
       " ['c16014'],\n",
       " ['eudract'],\n",
       " ['dose'],\n",
       " ['modifications'],\n",
       " ['may'],\n",
       " ['made'],\n",
       " ['throughout'],\n",
       " ['study'],\n",
       " ['based'],\n",
       " ['toxicities'],\n",
       " ['patients'],\n",
       " ['low'],\n",
       " ['creatinine'],\n",
       " ['clearance'],\n",
       " ['ml/min'],\n",
       " ['ml/min'],\n",
       " ['according'],\n",
       " ['local'],\n",
       " ['label/practice'],\n",
       " ['receive'],\n",
       " ['reduced'],\n",
       " ['lenalidomide'],\n",
       " ['dose'],\n",
       " ['mg'],\n",
       " ['daily'],\n",
       " ['days'],\n",
       " ['28-day'],\n",
       " ['cycle'],\n",
       " ['the'],\n",
       " ['lenalidomide'],\n",
       " ['dose'],\n",
       " ['may'],\n",
       " ['escalated'],\n",
       " ['mg'],\n",
       " ['daily'],\n",
       " ['cycles'],\n",
       " ['patient'],\n",
       " ['responding'],\n",
       " ['treatment'],\n",
       " ['tolerating'],\n",
       " ['treatment'],\n",
       " ['if'],\n",
       " ['renal'],\n",
       " ['function'],\n",
       " ['normalizes'],\n",
       " ['ie'],\n",
       " ['creatinine'],\n",
       " ['clearance'],\n",
       " ['ml/min'],\n",
       " ['ml/min'],\n",
       " ['according'],\n",
       " ['local'],\n",
       " ['label/practice'],\n",
       " ['patient'],\n",
       " ['continues'],\n",
       " ['tolerate'],\n",
       " ['treatment'],\n",
       " ['lenalidomide'],\n",
       " ['may'],\n",
       " ['escalated'],\n",
       " ['mg'],\n",
       " ['daily'],\n",
       " ['patients'],\n",
       " ['may'],\n",
       " ['continue'],\n",
       " ['receive'],\n",
       " ['treatment'],\n",
       " ['outlined'],\n",
       " ['previously'],\n",
       " ['cycles'],\n",
       " ['approximately'],\n",
       " ['months'],\n",
       " ['progressive'],\n",
       " ['disease'],\n",
       " ['pd'],\n",
       " ['unacceptable'],\n",
       " ['toxicity'],\n",
       " ['whichever'],\n",
       " ['comes'],\n",
       " ['first'],\n",
       " ['after'],\n",
       " ['cycles'],\n",
       " ['patients'],\n",
       " ['continue'],\n",
       " ['treatment'],\n",
       " ['randomization'],\n",
       " ['arm'],\n",
       " ['schedule'],\n",
       " ['modified'],\n",
       " ['dose'],\n",
       " ['levels'],\n",
       " ['study'],\n",
       " ['drug'],\n",
       " ['lendex'],\n",
       " ['reduce'],\n",
       " ['mln9708'],\n",
       " ['placebo'],\n",
       " ['dose'],\n",
       " ['mg'],\n",
       " ['reduce'],\n",
       " ['lenalidomide'],\n",
       " ['dose'],\n",
       " ['mg'],\n",
       " ['dexamethasone'],\n",
       " ['the'],\n",
       " ['treatment'],\n",
       " ['period'],\n",
       " ['study'],\n",
       " ['defined'],\n",
       " ['time'],\n",
       " ['patient'],\n",
       " ['receiving'],\n",
       " ['study'],\n",
       " ['drug'],\n",
       " ['regimen'],\n",
       " ['comprised'],\n",
       " ['28-day'],\n",
       " ['treatment'],\n",
       " ['cycles'],\n",
       " ['patients'],\n",
       " ['seen'],\n",
       " ['regular'],\n",
       " ['treatment'],\n",
       " ['cycle'],\n",
       " ['intervals'],\n",
       " ['participating'],\n",
       " ['study'],\n",
       " ['weekly'],\n",
       " ['first'],\n",
       " ['cycles'],\n",
       " ['twice'],\n",
       " ['treatment'],\n",
       " ['cycle'],\n",
       " ['third'],\n",
       " ['cycle'],\n",
       " ['treatment'],\n",
       " ['cycle'],\n",
       " ['remainder'],\n",
       " ['participation'],\n",
       " ['treatment'],\n",
       " ['period'],\n",
       " ['experience'],\n",
       " ['disease'],\n",
       " ['progression'],\n",
       " ['discontinue'],\n",
       " ['alternate'],\n",
       " ['reasons'],\n",
       " ['if'],\n",
       " ['patient'],\n",
       " ['discontinues'],\n",
       " ['treatment'],\n",
       " ['study'],\n",
       " ['regimen'],\n",
       " ['disease'],\n",
       " ['progression'],\n",
       " ['enter'],\n",
       " ['pfs'],\n",
       " ['follow-up'],\n",
       " ['period'],\n",
       " ['study'],\n",
       " ['patients'],\n",
       " ['assessed'],\n",
       " ['disease'],\n",
       " ['response'],\n",
       " ['progression'],\n",
       " ['independent'],\n",
       " ['review'],\n",
       " ['committee'],\n",
       " ['irc'],\n",
       " ['response'],\n",
       " ['assessed'],\n",
       " ['according'],\n",
       " ['international'],\n",
       " ['myeloma'],\n",
       " ['working'],\n",
       " ['group'],\n",
       " ['imwg'],\n",
       " ['criteria'],\n",
       " ['patients'],\n",
       " ['every'],\n",
       " ['cycle'],\n",
       " ['treatment'],\n",
       " ['period'],\n",
       " ['subsequently'],\n",
       " ['every'],\n",
       " ['weeks'],\n",
       " ['pfs'],\n",
       " ['follow-up'],\n",
       " ['period'],\n",
       " ['disease'],\n",
       " ['progression'],\n",
       " ['after'],\n",
       " ['disease'],\n",
       " ['progression'],\n",
       " ['patients'],\n",
       " ['followed'],\n",
       " ['survival'],\n",
       " ['overall'],\n",
       " ['survival'],\n",
       " ['os'],\n",
       " ['follow-up'],\n",
       " ['period'],\n",
       " ['patients'],\n",
       " ['contacted'],\n",
       " ['every'],\n",
       " ['weeks'],\n",
       " ['death'],\n",
       " ['termination'],\n",
       " ['study'],\n",
       " ['sponsor'],\n",
       " ['study'],\n",
       " ['population'],\n",
       " ['adult'],\n",
       " ['patients'],\n",
       " ['confirmed'],\n",
       " ['diagnosis'],\n",
       " ['symptomatic'],\n",
       " ['mm'],\n",
       " ['received'],\n",
       " ['previous'],\n",
       " ['anti-'],\n",
       " ['myeloma'],\n",
       " ['treatment'],\n",
       " ['transplant'],\n",
       " ['eligible'],\n",
       " ['candidates'],\n",
       " ['treatment'],\n",
       " ['lendex'],\n",
       " ['enrolled'],\n",
       " ['study'],\n",
       " ['duration'],\n",
       " ['study'],\n",
       " ['the'],\n",
       " ['duration'],\n",
       " ['study'],\n",
       " ['including'],\n",
       " ['enrollment'],\n",
       " ['treatment'],\n",
       " ['follow-up'],\n",
       " ['approximately'],\n",
       " ['months'],\n",
       " ['including'],\n",
       " ['27-month'],\n",
       " ['enrollment'],\n",
       " ['period'],\n",
       " ['additional'],\n",
       " ['60-month'],\n",
       " ['5-year'],\n",
       " ['follow-up'],\n",
       " ['last'],\n",
       " ['patient'],\n",
       " ['enrolled'],\n",
       " ['confidential'],\n",
       " ['mln9708'],\n",
       " ['clinical'],\n",
       " ['study'],\n",
       " ['protocol'],\n",
       " ['c16014'],\n",
       " ['eudract'],\n",
       " ['study'],\n",
       " ['overview'],\n",
       " ['diagram'],\n",
       " ['patients'],\n",
       " ['low'],\n",
       " ['creatinine'],\n",
       " ['clearance'],\n",
       " ['ml/min'],\n",
       " ['ml/min'],\n",
       " ['according'],\n",
       " ['local'],\n",
       " ['label/practice'],\n",
       " ['receive'],\n",
       " ['reduced'],\n",
       " ['lenalidomide'],\n",
       " ['dose'],\n",
       " ['mg'],\n",
       " ['daily'],\n",
       " ['days'],\n",
       " ['28-day'],\n",
       " ['cycle'],\n",
       " ['the'],\n",
       " ['lenalidomide'],\n",
       " ['dose'],\n",
       " ['may'],\n",
       " ['escalated'],\n",
       " ['mg'],\n",
       " ['daily'],\n",
       " ['cycles'],\n",
       " ['patient'],\n",
       " ['responding'],\n",
       " ['treatment'],\n",
       " ['tolerating'],\n",
       " ['treatment'],\n",
       " ['if'],\n",
       " ['renal'],\n",
       " ['function'],\n",
       " ['normalizes'],\n",
       " ['ie'],\n",
       " ['creatinine'],\n",
       " ['clearance'],\n",
       " ['ml/min'],\n",
       " ['ml/min'],\n",
       " ['according'],\n",
       " ['local'],\n",
       " ['label/practice'],\n",
       " ['patient'],\n",
       " ['continues'],\n",
       " ['tolerate'],\n",
       " ['treatment'],\n",
       " ['lenalidomide'],\n",
       " ['may'],\n",
       " ['escalated'],\n",
       " ['mg'],\n",
       " ['daily'],\n",
       " ['b'],\n",
       " ['patients'],\n",
       " ['years'],\n",
       " ['age'],\n",
       " ['randomization'],\n",
       " ['receive'],\n",
       " ['reduced'],\n",
       " ['dexamethasone'],\n",
       " ['dose'],\n",
       " ['mg'],\n",
       " ['c'],\n",
       " ['if'],\n",
       " ['dose'],\n",
       " ...]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "var01"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "25467"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(lst[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "25467"
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(var01)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "13409"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(var02)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#print(list_of_list[0])\n",
    "a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    " "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim.models import Word2Vec"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "unsupported operand type(s) for +: 'int' and 'str'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-97-156e2036cae1>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[0;31m# train model\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 2\u001b[0;31m \u001b[0mmodel\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mWord2Vec\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mwords\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmin_count\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msize\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;36m10\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      3\u001b[0m \u001b[0;31m# summarize the loaded model\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmodel\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m \u001b[0;31m# summarize vocabulary\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/media/hadoop/2EB21077B21045AD/Study/Environments/TA_NN_NLP/lib/python3.5/site-packages/gensim/models/word2vec.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, sentences, size, alpha, window, min_count, max_vocab_size, sample, seed, workers, min_alpha, sg, hs, negative, cbow_mean, hashfxn, iter, null_word, trim_rule, sorted_vocab, batch_words, compute_loss, callbacks)\u001b[0m\n\u001b[1;32m    525\u001b[0m             \u001b[0mbatch_words\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mbatch_words\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtrim_rule\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtrim_rule\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msg\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0msg\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0malpha\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0malpha\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwindow\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mwindow\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mseed\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mseed\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    526\u001b[0m             \u001b[0mhs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mhs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnegative\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mnegative\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcbow_mean\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcbow_mean\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmin_alpha\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mmin_alpha\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcompute_loss\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcompute_loss\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 527\u001b[0;31m             fast_version=FAST_VERSION)\n\u001b[0m\u001b[1;32m    528\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    529\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_do_train_job\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msentences\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0malpha\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minits\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/media/hadoop/2EB21077B21045AD/Study/Environments/TA_NN_NLP/lib/python3.5/site-packages/gensim/models/base_any2vec.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, sentences, workers, vector_size, epochs, callbacks, batch_words, trim_rule, sg, alpha, window, seed, hs, negative, cbow_mean, min_alpha, compute_loss, fast_version, **kwargs)\u001b[0m\n\u001b[1;32m    333\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msentences\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mGeneratorType\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    334\u001b[0m                 \u001b[0;32mraise\u001b[0m \u001b[0mTypeError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"You can't pass a generator as the sentences argument. Try an iterator.\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 335\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbuild_vocab\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msentences\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtrim_rule\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtrim_rule\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    336\u001b[0m             self.train(\n\u001b[1;32m    337\u001b[0m                 \u001b[0msentences\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtotal_examples\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcorpus_count\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mepochs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mepochs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstart_alpha\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0malpha\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/media/hadoop/2EB21077B21045AD/Study/Environments/TA_NN_NLP/lib/python3.5/site-packages/gensim/models/base_any2vec.py\u001b[0m in \u001b[0;36mbuild_vocab\u001b[0;34m(self, sentences, update, progress_per, keep_raw_vocab, trim_rule, **kwargs)\u001b[0m\n\u001b[1;32m    484\u001b[0m             trim_rule=trim_rule, **kwargs)\n\u001b[1;32m    485\u001b[0m         \u001b[0mreport_values\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'memory'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mestimate_memory\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvocab_size\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mreport_values\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'num_retained_words'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 486\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtrainables\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mprepare_weights\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mhs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mnegative\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mwv\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mupdate\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mupdate\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvocabulary\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvocabulary\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    487\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    488\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mbuild_vocab_from_freq\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mword_freq\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkeep_raw_vocab\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcorpus_count\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtrim_rule\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mupdate\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/media/hadoop/2EB21077B21045AD/Study/Environments/TA_NN_NLP/lib/python3.5/site-packages/gensim/models/word2vec.py\u001b[0m in \u001b[0;36mprepare_weights\u001b[0;34m(self, hs, negative, wv, update, vocabulary)\u001b[0m\n\u001b[1;32m   1400\u001b[0m         \u001b[0;31m# set initial input/projection and hidden weights\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1401\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mupdate\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1402\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreset_weights\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mhs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnegative\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwv\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1403\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1404\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mupdate_weights\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mhs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnegative\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwv\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/media/hadoop/2EB21077B21045AD/Study/Environments/TA_NN_NLP/lib/python3.5/site-packages/gensim/models/word2vec.py\u001b[0m in \u001b[0;36mreset_weights\u001b[0;34m(self, hs, negative, wv)\u001b[0m\n\u001b[1;32m   1417\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mi\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mxrange\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mwv\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvocab\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1418\u001b[0m             \u001b[0;31m# construct deterministic seed from word AND seed argument\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1419\u001b[0;31m             \u001b[0mwv\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvectors\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mseeded_vector\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mwv\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mindex2word\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mseed\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwv\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvector_size\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1420\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mhs\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1421\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msyn1\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mzeros\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mwv\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvocab\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlayer1_size\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdtype\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mREAL\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mTypeError\u001b[0m: unsupported operand type(s) for +: 'int' and 'str'"
     ]
    }
   ],
   "source": [
    "    # train model\n",
    "model = Word2Vec(words, min_count=1, size = 10)\n",
    "    # summarize the loaded model\n",
    "print(model)\n",
    "    # summarize vocabulary\n",
    "words = list(model.wv.vocab)\n",
    "print(words)\n",
    "     #C16014\n",
    "\n",
    "\n",
    "    # access vector for one word\n",
    "print(model['randomized'])\n",
    "    # save model\n",
    "model.save('model.bin')\n",
    "    # load model\n",
    "new_model = Word2Vec.load('model.bin')\n",
    "print(new_model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "47232"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "open('C16014_cleaned.txt','w').write(str(words))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Word2Vec(vocab=2586, size=10, alpha=0.025)\n",
      "['mln9708', 'clinical', 'study', 'protocol', 'c16014', 'eudract', 'a', 'phase', 'randomized', 'double-blind', 'multicenter', 'comparing', 'oral', 'plus', 'lenalidomide', 'dexamethasone', 'versus', 'placebo', 'adult', 'patients', 'with', 'newly', 'diagnosed', 'multiple', 'myeloma', 'number', 'indication', 'sponsor', 'therapeutic', 'area', 'history', 'original', 'approved', 'millennium', 'pharmaceuticals', 'inc', 'oncology', 'february', 'landsdowne', 'street', 'cambridge', 'ma', 'usa', 'telephone', 'note', 'if', 'document', 'electronically', 'electronic', 'approval', 'signatures', 'may', 'found', 'end', 'dixie-lee', 'esseltine', 'md', 'vice', 'president', 'research', 'designee', 'signature', 'date', 'dd', 'month', 'yyyy', 'ai-min', 'hui', 'phd', 'global', 'lead', 'confidentiality', 'statement', 'the', 'information', 'contained', 'herein', 'confidential', 'proprietary', 'property', 'unauthorized', 'use', 'disclosure', 'without', 'prior', 'written', 'authorization', 'expressly', 'prohibited', 'summary', 'title', 'approximately', 'objectives', 'primary', 'objective', 'to', 'determine', 'whether', 'addition', 'improves', 'progression-free', 'survival', 'pfs', 'newly-diagnosed', 'ndmm', 'key', 'secondary', 'rate', 'complete', 'response', 'cr', 'overall', 'os', 'pain', 'assessed', 'brief', 'inventory', 'short', 'form', 'bpi-sf', 'analgesic', 'other', 'orr', 'including', 'partial', 'pr', 'good', 'vgpr', 'time', 'ttr', 'duration', 'dor', 'progression', 'ttp', 'safety', 'assess', 'change', 'health', 'status', 'measured', 'functioning', 'symptoms', 'patient-reported', 'outcome', 'pro', 'instrument', 'european', 'organization', 'treatment', 'cancer', 'quality', 'life', 'questionnaire', 'eortc', 'qlq-c30', 'my-20', 'module', 'high-risk', 'cytogenetic', 'patient', 'groups', 'defined', 'following', 'abnormalities', '+1q', 'del', 'evaluate', 'relationship', 'polymorphisms', 'proteasome', 'nfkb-related', 'genes', 'psmb1', 'traf-3', 'circulating', 'levels', 'using', 'blood', 'samples', 'frequency', 'detection', 'minimal', 'residual', 'disease', 'via', 'flow', 'cytometry', 'impact', 'collect', 'pharmacokinetic', 'pk', 'data', 'contribute', 'population', 'analyses', 'skeletal-related', 'events', 'eg', 'new', 'fractures', 'excluding', 'vertebral', 'compression', 'rib', 'irradiation', 'surgery', 'bone', 'spinal', 'cord', 'baseline', 'last', 'assessment', 'exploratory', 'utilization', 'hu', 'euroqol', '5-dimensional', 'eq-5d', 'potential', 'response/', 'resistance', 'mutations', 'signaling', 'pathways', 'determined', 'clinically', 'meaningful', 'ras/raf', 'marrow', 'aspirates', 'tumor', 'gene', 'expression', 'patterns', 'nfkb', 'protein', 'synthesis', 'well', 'pathway', 'transcript', 'mechanisms', 'treatment-emergent', 'somatic', 'subunits', 'activity', 'tumors', 'initially', 'respond', 'therapy', 'exhibit', 'progressive', 'effects', 'changes', 'mineral', 'density', 'dual-energy', 'x-ray', 'absorptiometry', 'dexa', 'metabolism', 'biomarkers', 'srankl/opg', 'dkk-1', 'resolution', 'improvement', 'peripheral', 'neuropathy', 'pn', 'occurs', 'grading', 'subsequent', 'monthly', 'visit', 'start', 'alternative', 'antineoplastic', 'months', 'occurred', 'whichever', 'comes', 'first', 'overview', 'design', 'this', 'efficacy', 'added', 'lendex', 'confirmed', 'diagnosis', 'symptomatic', 'mm', 'received', 'previous', 'anti-myeloma', 'ineligible', 'high-dose', 'stem', 'cell', 'transplantation', 'hdt-sct', 'age', 'ie', 'years', 'coexisting', 'conditions', 'per', 'investigator', 'judgment', 'candidates', 'standard', 'meet', 'eligibility', 'criteria', 'detailed', 'section', 'enrolled', 'screening', 'period', 'receive', 'either', 'fashion', 'background', 'eligible', 'ratio', 'arms', 'stratified', 'vs', 'international', 'staging', 'system', 'iss', 'stage', 'worst', 'score', 'mg', 'matching', 'capsule', 'days', '28-day', 'cycle', 'reduced', 'dose', 'modifications', 'made', 'throughout', 'based', 'toxicities', 'low', 'creatinine', 'clearance', 'ml/min', 'according', 'local', 'label/practice', 'daily', 'escalated', 'cycles', 'responding', 'tolerating', 'renal', 'function', 'normalizes', 'continues', 'tolerate', 'continue', 'outlined', 'previously', 'pd', 'unacceptable', 'toxicity', 'after', 'randomization', 'arm', 'schedule', 'modified', 'drug', 'reduce', 'receiving', 'regimen', 'comprised', 'seen', 'regular', 'intervals', 'participating', 'weekly', 'twice', 'third', 'remainder', 'participation', 'experience', 'discontinue', 'alternate', 'reasons', 'discontinues', 'enter', 'follow-up', 'independent', 'review', 'committee', 'irc', 'working', 'group', 'imwg', 'every', 'subsequently', 'weeks', 'followed', 'contacted', 'death', 'termination', 'anti-', 'transplant', 'enrollment', '27-month', 'additional', '60-month', '5-year', 'diagram', 'b', 'c', 'remain', 'level', 'beyond', 'see', 'table', 'of', 'procedures', 'g', 'n', 'e', 'r', 's', 'c1', 'c2', 'c3', 'through', 'c4', 'c13', 'wk', 't', 'f', 'window', 'informed', 'consent', 'inclusion/exclusion', 'criteriab', 'demographics', 'medical', 'physical', 'exam', 'symptom-directed', 'ecog', 'performance', 'vital', 'signs', 'height', 'cm', 'weight', 'kg', 'pregnancy', 'testd', '12-lead', 'ecg', 'hematology', 'laboratorye', 'chemistry', 'thyroid', 'testing', 'urinalysis', 'eortc-qlq-c30', 'my-20g', 'eq-5dg', 'x', 'xc', 'xf', 'xh', 'xi', '24-hour', 'also', 'unscheduled', 'asssessment', 'visits', 'scan', 'skeletal', 'survey', 'radiographic', 'assessmentl', '\\uf0622-microglobulin', 'm-protein', 'measurements', 'spep', 'upep', '24hr', 'urine', 'collection', 'serum', 'free', 'light', 'chain', 'assay', 'immunofixation', 'urinen', 'quantification', 'igo', 'aspiration', 'molecular', 'analysis', 'xm', 'xp', 'xq', 'xj', 'xk', 'cytogenetics', 'diseases', 'biomarker', 'plasma', 'sample', 'germline', 'dna', 'adverse', 'event', 'reporting', 'concomitant', 'medications/procedures', 'narcotic', 'malignancy', 'xr', 'xt', 'recorded', 'regimenu', 'serious', 'pretreatment', 'collected', 'signing', 'continuous', 'administration', 'mln9708/placebo', 'abbreviations', 'd', 'day', 'deletion', 'eastern', 'cooperative', 'electrophoresis', 'translocation', 'week', 'tests', 'performed', 'occasional', 'allowed', 'holidays', 'vacations', 'administrative', 'shifted', 'assessments', 'dosing', 'must', 'ensure', 'completed', 'extenuating', 'circumstances', 'prevent', 'beginning', 'completing', 'scheduled', 'procedure', 'within', 'permission', 'mpi/designee', 'clinician', 'required', 'discontinuing', 'confirmation', 'taken', 'countries', 'except', 'canada', 'females', 'childbearing', 'fcbp', 'two', 'medically', 'supervised', 'negative', 'sensitivity', 'least', 'miu/ml', 'even', 'abstinence', 'chosen', 'method', 'contraception', 'one', 'test', 'obtained', 'hours', 'on', 'package', 'insert', 'menstrual', 'irregular', 'occur', 'for', 'discontinuation', 'not', 'apply', 'laboratory', 'evaluations', 'central', 'decisions', 'results', 'used', 'however', 'still', 'sent', 'labs', 'panels', 'done', 'frequently', 'investigators', 'discretion', 'acute', 'management', 'teaes', 'outcomes', 'encounters', 'administered', 'h', 'etc', 'during', 'phone', 'require', 'clinic', 'j', 'scans', 'lumbar', 'spine', 'femoral', 'neck', 'total', 'body', 'year', 'annually', 'k', 'minimum', 'more', 'frequent', 'suspected', 'increased', 'lesions', 'l', 'documented', 'extramedullary', 'ct/pet-ct/mri', 'modality', 'kept', 'consistent', 'repeated', 'confirm', 'undetectable', 'perform', 'immunoglobulins', 'igm', 'igg', 'iga', 'points', 'specified', 'quantitative', 'igd', 'ige', 'needed', 'rare', 'antibody', 'igs', 'p', 'lab', 'only', 'considered', 'possibly', 'm-', 'investigate', 'applicable', 'q', 'aspirate', 'second', 'pull', 'preferred', 'an', 'relapse', 'optional', 'highly', 'recommended', 'locally', 'site', 'capability', 'sufficient', 'specimen', 'available', 'possible', '+1q21', 'translocations', 'ictp', 'balp', 'predose', 'sampling', 'each', 'u', 'when', 'evaluation', 'record', 'grade', 'contrast', 'ae', 'increases', 'maximum', 'reached', 'return', 'second-line', 'hour', 'predoseb', 'predosea', 'due', 'allowable', '2-day', 'non-dosing', 'contents', 'list', 'tables', 'figures', 'and', 'glossary', 'terms', 'definitions', 'rationale', 'scientific', 'under', 'next-generation', 'inhibitor', 'nonclinical', 'trial', 'iv', 'formulation', 'pharmacokinetics', 'combination', 'selection', 'characteristics', 'risks', 'benefits', 'endpoints', 'endpoint', 'inclusion', 'exclusion', 'article', 'matched', 'therapies', 'dose-modification', 'guidelines', 'modification', 'delays', 'reductions', 'discontinuations', 'adjustments', 'hematologic', 'nonhematologic', 'dexamethasone-related', 'recovery', 'before', 'next', 'excluded', 'medications', 'permitted', 'precautions', 'restrictions', 'requirements', 'blinding', 'unblinding', 'description', 'investigational', 'agents', 'preparation', 'reconstitution', 'dispensing', 'packaging', 'labeling', 'storage', 'handling', 'accountability', 'protocol-specified', 'materials', 'conduct', 'personnel', 'organizations', 'arrangements', 'recruitment', 'assignments', 'examination', 'electrocardiogram', 'utility', 'measurement', 'immunoglobulin', 'ig', 'compliance', 'completion', 'replacement', 'withdrawal', 'from', 'statistical', 'methods', 'determination', 'size', 'stratification', 'populations', 'missing', 'unused', 'spurious', 'demographic', 'economics', 'interim', 'committees', 'steering', 'monitoring', 'definition', 'recording', 'observation', 'exposure', 'birth', 'practice', 'assurance', 'case', 'report', 'ethical', 'considerations', 'on-site', 'audits', 'responsibility', 'product', 'complaints', 'closure', 'retention', 'agreement', 'appendices', 'scale', 'diagnostic', 'cockcroft-gault', 'equation', 'durie-salmon', 'steroid', 'equivalent', 'doses', 'world', 'steps', 'analgesics', 'ome', 'conversions', 'morphine', 'inventory-short', 'qlq-my20', 'version', 'references', 'trials', 'intravenous', 'ongoing', 'studies', 'adjustment', 'thrombocytopenia', 'neutropenia', 'rash', 'reduction', 'revlimid®', 'dexamethasone–related', 'capsules', 'medication', 'categorized', 'who', 'i', 'ii', 'iii', 'parenteral', 'opioid', 'equivalences', 'relative', 'potency', 'drugs', 'compared', 'conversion', 'opioids', 'transdermal', 'fentanyl', 'figure', 'no', 'apparent', 'between', 'bsa', 'abbreviation', '5-ht3', 'al', 'alp', 'alt', 'anc', 'asco', 'ast', 'asct', 'auc', 'bcrp', 'braf', 'bun', 'cbc', 'term', '5-hydroxytryptamine', 'serotonin', 'receptor', 'systemic', 'alkaline', 'phosphatase', 'alanine', 'aminotransferase', 'absolute', 'neutrophil', 'count', 'american', 'society', 'aspartate', 'autologous', 'concentration', 'curve', 'breast', 'gene/gene', 'human', 'homolog', 'murine', 'sarcoma', 'viral', 'oncogene', 'surface', 'urea', 'nitrogen', 'cdf', 'cl', 'cmax', 'cmh', 'co2', 'ct', 'ctcae', 'cyp', 'ddi', 'dlt', 'dvt', 'ecrf', 'edc', 'qlc-c30', 'eot', 'eq', 'vas', 'esmo', 'eu', 'fa', 'fda', 'gcp', 'g-csf', 'gi', 'gm-csf', 'hdt-asct', 'hiv', 'cumulative', 'distribution', 'single-dose', 'occurrence', 'peak', 'cochran-mantel-haenszel', 'carbon', 'dioxide', 'computed', 'tomography', 'common', 'cytochrome', 'p450', 'drug-drug', 'interaction', 'dose-limiting', 'deoxyribonucleic', 'acid', 'deep', 'vein', 'thrombosis', 'capture', 'visual', 'analogue', 'union', 'final', 'united', 'states', 'food', 'female', 'granulocyte', 'colony', 'stimulating', 'factor', 'gastrointestinal', 'macrophage-colony', 'stem-cell', 'immunodeficiency', 'virus', 'ia', 'ib', 'ic50', 'icf', 'ich', 'idmc', 'iec', 'ikb', 'imid', 'immpact', 'inr', 'ir', 'irb', 'itt', 'iud', 'ixrs', 'k-m', 'kras', 'ldh', 'lmwh', 'locf', 'mds', 'meddra', 'mid', 'mp', 'mpi', 'brochure', 'producing', 'inhibition', 'conference', 'harmonisation', 'ethics', 'kappa', 'immunomodulating', 'initiative', 'normalized', 'immunophenotypic', 'institutional', 'board', 'intent-to-treat', 'intrauterine', 'device', 'intravenously', 'interactive', 'voice/', 'web', 'kaplan', 'meier', 'kirsten', 'rat', 'lactate', 'dehydrogenase', 'heparin', 'carried', 'forward', 'myelodysplastic', 'syndrome', 'dictionary', 'regulatory', 'activities', 'minimally', 'important', 'difference', 'inc.', 'affiliates', 'melphalan', 'prednisone', 'mpr', 'mpr-r', 'mrd', 'mri', 'mrp2', 'mtd', 'nccn', 'nci', 'nras', 'nsaid', 'pe', 'pet', 'pet-ct', 'p-gp', 'pi', 'po', 'poems', 'pres', 'qd', 'qol', 'revlimid', 'maintenance', 'magnetic', 'resonance', 'imaging', 'multidrug', 'associated', 'tolerated', 'national', 'comprehensive', 'network', 'institute', 'terminology', 'nuclear', 'kappa-b', 'neuroblastoma', 'non-steroidal', 'anti-inflammatory', 'pulmonary', 'embolism', 'positron', 'emission', 'tomography-computed', 'p-glycoprotein', 'mouth', 'orally', 'polyneuropathy', 'organomegaly', 'endocrinopathy', 'monoclonal', 'gammopathy', 'skin', 'remission', 'posterior', 'reversible', 'encephalopathy', 'proteosome', 'sub-unit', 'beta', 'quaque', 'die', 'qtc', 'rd', 'rral', 'rrmm', 'sae', 'sap', 'scr', 'sct', 'sd', 'sma', 'smpc', 'sre', 't1/2', 'teae', 'tmax', 'traf3', 'tw', 'uln', 'us', 'v2', 'vmp', 'vrd', 'rate-corrected', 'qt', 'interval', 'millisec', 'electrocardiograph', 'relapsed', 'and/or', 'refractory', 'amyloidosis', 'plan', 'stringent', 'stable', 'attachment', 'terminal', 'disposition', 'half-life', 'reach', 'tnf', 'receptor-associated', 'upper', 'limit', 'normal', 'range', 'volume', 'compartment', 'velcade', 'bortezomib', 'follow-', 'prospective', 'screened', 'receives', 'certain', 'stop', 'reason', 'appropriate', 'conducted', 'internet', 'b-cell', 'malignant', 'cells', 'remains', 'incurable', 'despite', 'advances', 'novel', 'inhibitors', 'characterized', 'accumulation', 'organs', 'result', 'failure', 'destruction', 'hypercalcemia', 'it', 'constitutes', 'reported', 'neoplasms', 'cancers', 'worldwide', 'in', 'americas', 'western', 'cases', 'people', 'although', 'less', 'asian', 'incidences', 'almost', '4-fold', 'past', 'younger', 'onset', 'invasive', 'favorable', 'prognosis', 'sensitive', 'many', 'cytotoxic', 'alkylating', 'anthracyclines', 'corticosteroids', 'initial', 'over', 'decade', 'significant', 'achievements', 'expanding', 'options', 'thalidomide', 'these', 'regimens', 'extended', 'time-to-progression', 'introduction', 'significantly', 'improved', 'adding', 'vista', 'demonstrated', 'persistent', 'benefit', 'median', 'increase', 'mo', 'hr', 'palumbo', 'onto', 'longer', 'hazard', 'need', 'better', 'demonstrate', 'variable', 'responses', 'treatments', 'decreasing', 'likelihood', 'become', 'ultimately', 'left', 'effort', 'expand', 'armamentarium', 'target', 'developed', 'small', 'molecule', '20s', 'validated', 'effective', 'success', 'subcutaneous', 'velcade®', 'first-in-class', 'building', 'malignancies', 'improve', 'pharmacology', 'agent', 'provide', 'convenient', 'mode', 'like', 'peptide', 'boronic', 'analog', 'citrate', 'ester', 'mln2238', 'biologically', 'active', 'potently', 'reversibly', 'selectively', 'inhibits', 'formulated', 'chemical', 'properties', 'delivery', 'rapidly', 'hydrolyzes', 'upon', 'contact', 'aqueous', 'solutions', 'demonstrates', 'faster', 'dissociation', 'resulting', 'enhanced', 'penetration', 'exhibits', 'antitumor', 'broader', 'xenografts', 'prolonged', 'tissue', 'preferentially', 'binds', 'nm', 'at', 'higher', 'concentrations', 'sites', 'selective', 'tested', 'panel', 'proteases', 'values', '\\uf06dm', 'kinases', 'receptors', 'different', 'half-lives', 'reflecting', 'differences', 'on-off', 'binding', 'kinetics', 'minutes', 'respectively', 'anticipated', 'regarding', 'absorption', 'excretion', 'toxicology', 'humans', 'tolerability', 'pharmacodynamics', 'as', 'april', 'treated', 'across', 'enrolling', 'sponsor-led', 'twice-weekly', 'evaluated', 'regardless', 'route', 'given', '21-day', 'development', 'focused', 'yet', 'related', 'dyscrasia', 'looking', 'interactions', 'effect', 'bioavailability', 'uses', 'additionally', 'c16001', 'advanced', 'lymphoma', 'c16002', 'there', 'investigating', 'solid', 'lymphomas', 'single-agent', 'investigated', 'included', 'trial/', 'single', 'mg/m2', 'closed', '3.11mg/m2', 'tbd', 'w', 'actively', 'differing', 'currently', 'c16003', 'c16004', 'c16005', 'c16006', 'a-', 'b-', 'nausea', 'vomiting', 'diarrhea', 'syncope', 'rp2da', 'fixed', 'switched', 'relevant', '2.23mg/m2', 'aa', '3-3.7-mg', 'subileus', 'ba', '3-5.5-mg', 'c16007', 'c16008', 'esophageal', 'ulcer', '4-5.5-mg', 'dosea', 'dyspnea', 'rise', 'cardiac', 'arrest', '3.0-3.7-mg', 'c16009', '5.5-mg', 'rp2d=', 'approximate', 'equivalence', 'mg~', 'further', 'details', 'planned', 'provided', 'show', 'multi-exponential', 'rapid', 'largely', 'absorbed', 'stochastic', 'simulations', 'exposures', 'individual', 'recommendation', 'appears', 'major', 'elimination', 'negligible', 'urinary', 'parent', 'vitro', 'liver', 'microsomes', 'metabolized', 'enzymes', 'cyps', 'non-cyp', 'enzymes/proteins', 'rank', 'order', 'biotransformation', 'isozymes', '3a4', '1a2', '2d6', '2c9', '2c19', 'time-dependent', 'cyp3a4/5', 'produce', 'ddis', 'inferred', 'strong', 'cyp3a4', 'cyp1a2', 'first-pass', 'moderate', 'contribution', 'cyp3a4-', 'cyp1a2-mediated', 'weak', 'substrate', 'efflux', 'pump', 'transporters', 'thus', 'risk', 'substrates', 'therefore', 'course', 'depends', 'ability', 'toxic', 'otherwise', 'hand', 'option', 'elderly', 'superiority', 'moreover', 'often', 'able', 'accompanying', 'because', 'improvements', 'pronounced', 'hypothesized', 'lack', 'progress', 'treatment-related', 'burden', 'inability', 'deliver', 'efficacious', 'furthermore', 'heterogeneous', 'subset', 'particularly', 'frail', 'especially', 'challenging', 'treat', 'categorizing', 'fact', 'coupled', 'lagging', 'highlights', 'clear', 'develop', 'profiles', 'current', 'include', 'melphalan-containing', 'declining', 'recent', 'known', 'leukemia', 'non-melphalan', 'containing', 'immunomodulatory', 'individually', 'analogues', 'imids', 'changed', 'conventional', 'shown', 'rates', 'recognized', 'induction', 'nontransplant', 'care', 'select', 'availability', 'recently', 'high', 'transplant-eligible', '-ineligible', 'reports', 'similar', 'continued', 'delayed', 'usual', 'upfront', 'raised', 'questions', 'early', 'relapses', 'safer', 'challenge', 'combining', 'established', 'contemporary', 'ones', 'attempt', 'achieve', 'long-term', 'control', 'examine', 'feasibility', 'proposed', 'generation', 'support', 'chauhan', 'colleagues', 'work', 'model', 'systems', 'combined', 'triggers', 'synergistic', 'anti-multiple', 'supporting', 'purpose', 'front-line', 'consists', 'alone', 'mp-based', '+mp', 'chemotherapy', 'confirms', 'mp-alone', 'produced', 'health-related', 'professionals', 'recommend', 'glucocorticosteroid', 'low-dose', 'noted', 'illustrates', 'lenalidomide-dexamethasone', 'pharmacologic', 'profile', 'expected', 'translate', 'preclinical', 'supports', 'though', 'c16010', 'begun', 'forms', 'foundation', 'toxicological', 'generally', 'class-based', 'treatment-', 'emergent', 'cohorts', 'causality', 'discussed', 'overlapping', 'monitored', 'routine', 'observations', 'pathology', 'supported', 'vivo', 'predicted', 'allow', 'mouse', 'models', 'open-label', 'escalation', 'portion', 'evaluable', 'cohort', 'while', 'compromised', 'tolerable', 'decided', 'preliminary', 'suggests', 'manageable', 'encouraging', 'anti-tumor', 'observed', 'setting', 'cut', 'fatigue', 'aes', 'constipation', 'respiratory', 'infection', 'edema', 'anemia', 'fever', 'back', 'dysgeusia', 'primarily', 'erythematous', 'today', 'starting', 'translated', 'built', 'showed', 'described', '3-compartment', 'linear', 'covariate', 'indicate', 'interpatient', 'variability', 'parameters', 'affect', 'concentration-versus-', 'discernable', 'relatively', 'wide', 'm2', 'indicates', 'accordingly', 'mean', 'sq', 'provides', 'plot', 'color', 'identifies', 'blue', 'line', 'represents', 'regression', 'heterogeneity', 'therapeutics', 'partly', 'variation', 'subtypes', 'complex', 'biology', 'host', 'several', 'directly', 'combinations', 'deregulated', 'mapping', 'chromosome', 'highlight', 'links', 'regulator', 'whole', 'genome', 'sequencing', 'presence', 'present', 'much', 'highlighted', 'link', 'specific', 'raf/ras', 'wnt/\\uf062-catenin', 'activation', 'hypotheses', 'identify', 'limited', 'epigenetic', 'factors', 'specifically', 'variants', 'contributors', 'proteasome-related', 'relate', 'microenvironment', 'impacting', 'growth', 'associations', 'examined', 'reasonable', 'approach', 'differential', 'ratios', 'prognostic', 'increasing', 'correlating', 'targets', 'leads', 'possibility', 'prediction', 'retrospective', 'bortezomib-containing', 'leading', 'high-circulating', 'could', 'poor', 'marker', 'point', 'value', 'exploring', 'association', 'hyperdiploidy', 'neutral', '17p', 'amplification', '1q', 'impart', 'unfavorable', 'some', 'suggest', 'overcome', 'whereas', 'contradicting', 'dimopoulos', 'et', 'al.', 'context', 'lower', 'del13q', 'amp1q21', 'mainly', 'rd-treated', 'del17', 'worse', 'length', 'arise', 'differently', 'dropped', 'aggressive', 'myelomas', 'hypothesis', 'neben', 'del17p', 'adriamycin', 'vincristine', 'comparable', 'superior', 'carrying', 'abnormality', 'del17-positive', 'similarly', '3-year', 'optimal', 'evolved', 'normalization', 'morphology', 'light-chain', 'immunophenotyping', 'defines', 'specimens', 'threshold', 'cytometric', 'indicated', '-negative', 'experienced', 'cytometric-positive', 'paiva', 'salamanca', 'spain', 'pethema/gem', 'multivariate', 'cox', 'confidence', 'ci', 'feature', 'occurring', 'evidence', 'positive', 'disease-related', 'melphalan/prednisone', 'worsening', 'bisphosphonate', 'requirement', 'radiotherapy', 'build', 'studying', 'cutoff', 'includes', 'treatment-free', 'periods', 'discontinued', 'emerging', 'severity', 'slightly', 'differ', 'severe', 'managed', 'intervention', 'mitigate', 'inherent', 'closely', 'guidance', 'reducing', 'protocols', 'dosage', 'interruption', 'shows', 'evidenced', 'stabilization', 'others', 'studied', 'non-hodgkin', 'characterize', 'inventory-', 'nfkb-', 'documentation', 'cause', 'proportion', 'responders', 'scores', 'saes', 'comparison', 'postbaseline', 'estimate', 'classification', 'concentration-time', 'future', 'existing', 'collecting', 'transcripts', 'general', 'formal', 'part', '/designee', 'mga', 'mgb', 'mgc', 'none', 'all', 'quantified', 'intensity', 'degree', 'discomfort', 'location', 'likely', 'comorbidities', 'item', 'rated', 'self-reported', 'instruments', 'generic', 'measure', 'assessing', 'selected', 'elucidate', 'social', 'psychological/emotional', 'cognitive', 'electrocardiograms', 'ecgs', 'june', 'example', 'would', 'attend', 'statistically', 'claimed', 'unsuccessful', 'stopped', 'overwhelming', 'o', 'brien-', 'fleming', 'boundary', 'crossed', 'centers', 'north', 'america', 'europe', 'older', 'male', 'old', 'comorbid', 'condition', 'opinion', 'measurable', 'g/dl', 'g/l', 'mg/24', 'involved', 'mg/dl', 'mg/l', 'abnormal', '1,000/mm3', 'platelet', '75,000/mm3', 'transfusions', 'help', 'bilirubin', 'calculated', 'are', 'postmenopausal', 'or', 'surgically', 'sterile', 'have', 'medically-supervised', 'administering', 'dates', 'b.', 'c.', 'agree', 'true', 'lifestyle', 'periodic', 'calendar', 'ovulation', 'symptothermal', 'post-ovulation', 'acceptable', 'begin', 'reliable', 'same', 'refer', 'd.', 'e.', 'adhere', 'revassist®', 'program', 'participants', 'revaid®', 'canadian', 'minimisation', 'manual', 'commercial', 'supplies', 'sterilized', 'postvasectomy', 'barrier', 'entire', 'partner', 'successful', 'vasectomy', 'suitable', 'venous', 'access', 'study-required', 'take', 'concurrent', 'aspirin', 'enoxaparin', 'subcutaneously', 'allergic', 'published', 'prophylactic', 'anticoagulation', 'mandatory', 'thromboembolism', 'prophylaxis', 'voluntary', 'study-related', 'understanding', 'withdrawn', 'prejudice', 'willing', 'meeting', 'localized', 'radiation', 'long', 'exceed', '2-week', 'another', 'nonmelanoma', 'carcinoma', 'situ', 'type', 'undergone', 'resection', 'unwillingness', 'antithrombotic', 'lactating', 'breastfeeding', 'kyphoplasty', 'vertebroplasty', 'nervous', 'involvement', 'requiring', 'antibiotic', 'waldenstrom', 'macroglobulinemia', 'myeloproliferative', 'uncontrolled', 'cardiovascular', 'hypertension', 'arrhythmias', 'congestive', 'heart', 'unstable', 'angina', 'myocardial', 'infarction', 'fluvoxamine', 'enoxacin', 'ciprofloxacin', 'cyp3a', 'clarithromycin', 'telithromycin', 'itraconazole', 'voriconazole', 'ketoconazole', 'nefazodone', 'posaconazole', 'inducers', 'rifampin', 'rifapentine', 'rifabutin', 'carbamazepine', 'phenytoin', 'phenobarbital', 'ginkgo', 'biloba', 'st.', 'john', 'wort', 'hepatitis', 'illnesses', 'make', 'inappropriate', 'entry', 'interfere', 'proper', 'prescribed', 'psychiatric', 'illness/social', 'situation', 'allergy', 'excipients', 'various', 'formulations', 'swallow', 'comply', 'tolerance', 'products', 'protocol-specific', 'met', 'supervision', 'identified', 'subinvestigator', 'necessary', 'accommodate', 'interruptions', 'home', 'directed', 'instructions', 'referred', 'supplied', 'strengths', 'identical', 'shape', 'both', 'corresponding', 'instructed', 'water', 'break', 'chew', 'open', 'empty', 'stomach', 'sooner', 'meal', 'swallowed', 'ml', 'missed', 'soon', 'remembers', 'away', 'double', 'vomits', 'taking', 'repeat', 'resume', 'seek', 'emergency', 'staff', 'immediately', 'mg/day', 'milk', 'enough', 'elapsed', 'skipped', 'attributed', 'consultation', 'clinician/study', 'clarification', 'decision', 'requires', 'dependent', 'discussion', 'maximize', 'protecting', 'fall', '30,000/mm3', 'fourth', 'action', 'interrupt', 'maintain', 'follow', 'fifth', 'please', 'add', 'alphabetical', 'do', '109/l', 'myeloid', 'recommendations', 'actiona', '3mg', 'situations', 'interrupted', 'implemented', 'treating', 'physician', 'angioedema', 'findings', 'sequential', 'drug-related', 'drug/placebo', 'hold', 'judged', 'recover', 'recurrence', 'consider', 'permanently', 'delay', 'restart', 'attribution', 'ctc', 'definitions/', 'asymptomatic', 'loss', 'limiting', 'instrumental', 'living', 'adl', 'self', 'assistive', 'monitor', 'exception', 'determines', 'obtaining', 'lenalidomide-related', 'dysfunction', 'resolved', 'insert/smpc', 'impaired', 'thrombosis/embolism', 'stevens-johnson', 'sjs', 'epidermal', 'necrolysis', 'ten', 'exfoliative', 'bullous', 'lysis', 'adequate', 'insert/', 'modify', 'selection/modification', 'decreased', 'regularly', 'dyspepsia', 'gastric', 'duodenal', 'gastritis', 'hospitalization', 'pancreatitis', 'unresponsive', 'anasarca', 'neurological', 'confusion', 'mood', 'alteration', 'musculoskeletal', 'muscle', 'weakness', 'interfering', 'histamine-2', 'blockers', 'sucralfate', 'omeprazole', 'persist', 'measures', 'decrease', 'adequately', 'controlled', 'along', 'diuretics', 'persists', 'resolve', 'metabolic', 'hyperglycemia', 'insulin', 'hypoglycemics', 'satisfactory', 'follows', 'fails', 'initiation', 're-evaluated', 'retreatment', 'incomplete', 'metabolizing', 'enzyme', 'avoided', 'unless', 'unlike', 'inducer', 'medicinal', 'any', 'palliative', 'preexisting', 'lesion', 'millennium/designee', 'supportive', 'ecrfs', 'their', 'usage', 'reviewed', 'erythropoietin', 'minimized', 'transfused', 'red', 'platelets', 'digoxin', 'co-administered', 'accordance', 'bisphosphonates', 'encouraged', 'lytic', 'osteopenia', 'contraindicated', 'started', 'initiated', 'fluid', 'deficit', 'corrected', 'nonsteroidal', 'nsaids', 'nsaid-induced', 'embryo', 'fetus', 'structurally', 'teratogenic', 'substance', 'causes', 'life-threatening', 'defects', 'avoid', 'becoming', 'pregnant', 'impregnating', 'sexually', 'mature', 'woman', 'hysterectomy', 'bilateral', 'oophorectomy', 'naturally', 'amenorrhea', 'rule', 'consecutive', 'menses', 'preceding', 'salpingo-oophorectomy', 'amenorrheic', 'qualified', 'provider', 'contraceptive', 'examples', 'tubal', 'ligation', 'condom', 'diaphragm', 'spermicide', 'cervical', 'cap', 'pills', 'switch', 'listed', 'steroids', 'co-', 'against', 'lymphopenia', 'particular', 'reactivation', 'herpes', 'zoster', 'simplex', 'viruses', 'antiviral', 'acyclovir', 'valacyclovir', 'antivirals', 'hypotension', 'orthostatic', 'pressure', 'anorexia', 'manage', 'hypo-', 'thromboprophylaxis', 'warfarin', 'clopidogrel', 'ticlopidine', 'mentioned', 'anti-emetics', 'antagonists', 'emesis', 'anti-emetic', 'antidiarrheals', 'infectious', 'intake', 'maintained', 'dehydration', 'pruritus', 'lenalidomide-induced', 'generalized', 'maculopapular', 'morbilliform', 'urticarial', 'papular', 'warning/precaution', 'reactions', 'erythema', 'multiforme', 'areas', 'macular', 'bumps', 'pruritic', 'transient', 'spontaneously', 'topical', 'develops', 'thick', 'alcohol-free', 'emollient', 'cream', 'dry', 'stevens-', 'johnson', 'deadly', 'peeling', 'sores', 'symptomatically', 'punch', 'biopsies', 'histopathological', 'counts', 'reinitiated', 'thrombotic', 'thrombocytopenic', 'purpura', 'disorder', 'clots', 'vessels', 'petechiae', 'since', 'substantially', 'excreted', 'kidney', 'commonly', 'above-noted', 'until', 'discouraged', 'project', 'headache', 'seizures', 'abrupt', 'radiologic', 'reversed', 'instigating', 'blind', 'clinicians', 'blinded', 'unblinded', 'request', 'anticancer', 'outlines', 'securely', 'operating', 'records', 'dispensed', 'assignment', 'revealed', 'clinician/', 'knowledge', 'properly', 'ae/safety', 'issue', 'ae/', 'broken', 'breaking', 'manufactured', '2.3-mg', 'correspond', 'strength', 'differentiated', 'ivory', 'gray', 'flesh', 'pharmacy', 'finished', 'packaged', 'cold', 'foil-foil', 'blisters', 'child-resistant', 'carton', 'potentially', 'compounds', 'caution', 'exercised', 'labels', 'fulfill', 'governing', 'regulations', '4.0-mg', 'child-', 'resistant', 'wallet/carton', 'receipt', 'investigative', 'blister', 'dispensation', 'container', 'stored', 'refrigerated', '36°f', '46°f', '2°c', '8°c', 'excursions', 'brought', 'attention', 'retest', 'expiry', 'extensions', 'communicated', 'updated', 'shelf', 'take-home', 'store', 'cartons', 'rather', 'discarding', 'policy', 'reconciliation', 'returns', 'extreme', 'temperature', 'excursion', 'dealt', 'case-by-case', 'basis', 'handled', 'raising', 'dust', 'clean-up', 'operation', 'harmful', 'inhalation', 'ingestion', 'gloves', 'protective', 'clothing', 'worn', 'powder', 'minimize', 'contract', 'ventilated', 'washed', 'soap', 'material', 'pick', 'disposed', 'hazardous', 'waste', 'federal', 'state', 'copious', 'amounts', 'eyes', 'flush', 'notified', 'intact', 'sources', 'depending', 'regional', 'subjects', 'procurement', 'separate', 'supply', 'temperatures', 'manufacturer', 'tablets', 'label', 'ancillary', 'laboratories', 'vendors', 'full', 'database', 'strategies', 'referrals', 'physicians', 'advertisements', 'strategy', '/independent', 'envisioned', 'prisoners', 'might', 'subject', 'coercion', 'exploitation', 'assigned', 'code', 'country-', 'site-', 'patient-specific', 'centralized', 'strictly', 'sequentially', 'center', 'reused', 're-enter', 'timing', 'sections', 'race', 'ethnicity', 'sex', 'compiled', 'smoking', 'times', 'menstruation', 'regionally', 'breaks', 'counseled', 'fetal', 'iec/irbs', 'narcotics', 'nonserious', 'he/she', 'qrs', 'waveforms', 'shipment', 'hematological', 'hemoglobin', 'hematocrit', 'leukocytes', 'neutrophils', 'urate', 'phosphate', 'albumin', 'glucose', 'sodium', 'potassium', 'calcium', 'chloride', 'magnesium', 'hormone', 'tsh', 'ph', 'turbidity', 'gravity', 'ketones', 'occult', 'nitrite', 'urobilinogen', 'microscopic', 'encounter', 'inpatient/outpatient', 'admissions', 'homecare', 'qlq-30', 'incorporates', 'functional', 'scales', 'role', 'emotional', 'symptom', 'items', 'insomnia', 'appetite', 'financial', 'difficulties', 'recall', '20-items', 'subscales', 'image', 'perspective', 'side-effects', 'valid', 'takes', 'administer', 'consist', 'instituted', 'later', 'principal', 'tool', 'contains', 'designed', 'average', 'relieve', 'interference', 'walking', 'relations', 'sleep', 'enjoyment', 'employs', 'bad', 'imagine', 'medicines', 'agency', 'investigation', 'nociceptive', 'issued', 'released', 'discussing', 'conceptual', 'frameworks', 'framework', 'straightforward', 'concept', 'interest', 'queried', 'patient-recalled', 'amount', 'pages', 'descriptive', 'comprises', 'dimensions', 'mobility', 'pain/discomfort', 'anxiety/depression', 'respondent', 'self-rated', '20-cm', 'vertical', 'ranging', 'imaginable', 'best', 'roentgenography', 'believes', 'plain', 'films', 'clarity', 'place', 'sres', 'captured', 'delineate', 'radiographs', 'analyzed', 'utilized', 'cover', 'mutation', 'submitted', 'shipping', 'responded', 'consents', 'kappa/lambda', 'immunohistochemistry', 'immunofluorescence', 'biopsy', 'standards', 'instances', 'categories', 'subcategory', 'very', 'chains', 'category', 'hydrolysis', 'lc/ms/ms', 'candidate', 'mechanism', 'pathway-related', 'regulators', 'nfkb1', 'family', 'bortezomib-based', 'linked', 'undergoing', 'beneficial', 'formation', 'confirming', 'bone-alp', 'oc', 'markers', 'rankl', 'resorption', 'assessments/visits', 'e-mail', 'mail', 'security', 'indexes', 'department', 'pharmacovigilance', 'deaths', 'considers', 'posttreatment', 'irrespective', 'regime', 'terminates', 'violation', 'terminated', 'lost', 'once', 'consequence', 'tabulations', 'presented', 'display', 'deviation', 'variables', 'percent', 'categorical', 'kaplan-meier', 'curves', '25th', '50th', '75th', 'percentiles', '2-sided', 'cis', 'time-to-event', 'finalized', 'deviations', 'obtain', 'power', 'maintaining', 'powered', 'assuming', 'alpha', 'thereafter', 'dropout', 'estimated', 'significance', 'detect', 'log-rank', '18-month', 'opportunity', 'claim', 'brien-fleming', 'stopping', 'numbers', 'exactly', 'correspondingly', 'scheme', 'generated', 'statistician', 'team', 'actually', 'that', 'errors', 'per-protocol', 'pp', 'violations', 'exclude', 'response-evaluable', 'listings', 'erroneous', 'imputation', 'applied', 'carry', 'explored', 'post-baseline', 'counted', 'non-responder', 'instead', 'deal', 'summarized', 'gender', 'spending', 'lan-demets', 'whenever', 'reaches', 'family-wise', 'error', 'strongly', 'irc-', 'censored', 'compare', 'respect', 'unadjusted', 'medians', 'estimable', 'censoring', 'go', 'approaches', 'subgroup', 'logistic', 'odds', 'alive', 'apart', 'response-related', 'irc-assessed', 'achieved', 'descriptively', 'side', 'accompanied', 'pros', 'nausea/vomiting', 'constipation/diarrhea', 'main', 'status/quality', 'subscale', 'remaining', 'repeated-measures', 'mixed', 'variance', 'resource', 'statistics', 'stay', 'inpatient', 'outpatient', 'care-giver', 'qualify', 'surgical', 'confirmatory', 'step', 'separately', 'polymorphism', 'p11a', 'tabulated', 'overexpression', 'p53', 'mutational', 'sets', 'gene/pathway', 'binary', 'summarizing', 'percentages', 'absence', 'negativity', 'incidence', 'listing', 'actual', 'plotted', 'shift', 'graphical', 'displays', 'scatter', 'plots', 'understand', 'classified', 'types', 'proportions', 'percentage', 'divided', 'patient-years', 'pt-yrs', 'exponential', 'lifetime', 'constant', 'hazards', 'distinct', 'nature', 'signals', 'non-', 'clearly', 'enumerate', 'define', 'high-level', 'neuropathies', 'nec', 'grades', 'inclusive', 'permits', 'progression/death', 'boundaries', 'projected', 'representatives', 'formed', 'advice', 'publications', 'continuation', 'notify', 'authorities', 'periodically', 'meetings', 'prespecified', 'charter', 'reviews', 'accrual', 'ad', 'hoc', 'unexpected', 'unplanned', 'external', 'publication', 'competing', 'organ', 'class', 'narratives', 'on-study', 'withdrawals', 'archived', 'communicate', 'concerns', 'untoward', 'signed', 'participate', 'necessarily', 'causal', 'means', 'pharmaceutical', 'unintended', 'sign', 'finding', 'temporally', 'is', 'refers', 'hypothetically', 'caused', 'prolongation', 'paragraph', 'hospitalizations', 'disability', 'incapacity', 'substantial', 'disruption', 'person', 'functions', 'congenital', 'anomaly/birth', 'defect', 'threatening', 'jeopardize', 'involves', 'transmission', 'bronchospasm', 'intensive', 'room', 'dyscrasias', 'convulsions', 'dependency', 'abuse', 'organism', 'particle', 'prion', 'transmitting', 'transmissible', 'spongiform', 'pathogenic', 'nonpathogenic', 'synonymous', 'describe', 'minor', 'patient/event', 'usually', 'pose', 'threat', 'white', '1000/mm3', 'seriousness', 'serves', 'guide', 'defining', 'obligations', 'question', 'page', 'deterioration', 'indicating', 'underlying', 'faxing', 'aware', 'created', 'requested', 'information*', 'ppdi', 'helpline', 'fax', 'south', 'hospital', 'illness', 'existed', 'deteriorated', 'manner', 'earlier', 'yes', 'unrelated', 'chronic', 'intercurrent', 'es', 'pregnancies', 'reportable', 'facsimile', 'obstetrician-gynecologist', 'preferably', 'reproductive', 'counseling', 'becomes', 'ich-gcp', 'thoroughly', 'familiar', 'prepare', 'accurate', 'histories', 'pertinent', 'entered', 'secure', 'web-based', 'application', 'monitors', 'discuss', 'uninterpretable', 'audit', 'trail', 'affected', 'training', 'permit', 'correct', 'responsible', 'accuracy', 'completeness', 'timeliness', 'designated', 'representative', 'endorse', 'user', 'identification', 'correction', 'retain', 'trails', 'copy', 'archival', 'compact', 'disk', 'cd', 'media', 'placed', 'file', 'auditing', 'source', 'verify', 'ensures', 'irb/iec', 'safeguard', 'rights', 'well-being', 'diary', 'cards', 'updates', 'annual', 'revisions', 'documents', 'fully', 'explained', 'his/her', 'guardian', 'legal', 'documenting', 'privacy', 'communications', 'initials', 'publicly', 'extent', 'laws', 'approval/favorable', 'authority', 'ies', 'implementation', 'eliminate', 'immediate', 'submit', 'departures', 'iec/irb', 'inspection', 'direct', 'guaranteed', 'returned', 'disposal', 'complaint', 'verbal', 'implies', 'dissatisfaction', 'identity', 'purity', 'stability', 'individuals', 'medcomm', 'pending', 'call', 'ppd', 'competent', 'iecs', 'member', 'ended', 'prematurely', 'notification', 'terminating', 'party', 'warrant', 'insufficient', 'adherence', 'unevaluable', 'plans', 'suspend', 'should', 'right', 'cease', 'password', 'concluded', 'devices', 'premature', 'providing', 'retained', 'marketing', 'withdraws', 'keeping', 'custody', 'transferred', 'accept', 'privileged', 'agrees', 'accomplish', 'purposes', 'understood', 'obligation', 'toward', 'disclosed', 'corporate', 'partners', 'consultants', 'institution', 'publish', 'disclose', 'pursuant', 'advise', 'presentations', 'read', 'inform', 'assist', 'responsibilities', 'printed', 'name', 'predisease', 'restriction', 'ambulatory', 'restricted', 'physically', 'strenuous', 'sedentary', 'housework', 'office', 'bed', 'capable', 'self-care', 'unable', 'up', 'waking', 'confined', 'chair', 'bedridden', 'completely', 'disabled', 'can', 'totally', 'dead', 'oken', 'creech', 'rh', 'tormey', 'dc', 'horton', 'davis', 'te', 'mcfadden', 'am', 'clin', 'oncol', 'myelomaa', 'three', 'biopsy-proven', 'plasmacytoma', 'urineb', 'myeloma-related', 'elevation', 'insufficiency', 'osteoporosisd', 'myeloma.org', 'accessed', 'january', 'stages', 'a/b', 'durie/salmon', 'smoldering', 'indolent', 'detected', 'non-secretory', 'variety', 'end-organ', 'dysfunctions', 'occasionally', 'such', 'proven', 'solitary', 'osteoporosis', 'sole', 'males', '140-age', '140–age', '\\uf06dmol/l', 'cockcroft', 'dw', 'gault', 'mh', 'nephron', 'neither', 'iiia', 'durie', 'bg', 'salmon', 'se', 'correlation', 'mass', 'presenting', 'features', 'ß2-microglobulin', 'structure', 'm', 'component', 'production', 'bence', 'jones', 'g/24', 'sub', 'classifications', 'glucocorticoid', 'mineralicorticoid', 'cortisone', 'hydrocortisone', 'prednisolone', 'methylprednisolone', 'knoben', 'je', 'anderson', 'handbook', '6th', 'ed', 'intelligence', 'pub', 'acetaminophen', 'caffeine', 'butalbital', 'tab', 'elixir', 'mg/5ml', 'soln', 'mg/ml', 'mg/2.5ml', 'mg/5', 'suppos', 'susp', 'w/', 'carbonate', 'acetaminophen-butalbital', 'acetaminophen-caffeine-butalbital', 'aluminum', 'glycolate', 'hydroxide', 'phenacetin', 'buffered', 'carbonate-al', 'glycinate', 'ec', 'aspirin-acetaminophen', 'aspirin-acetaminophen-caffeine', 'aspirin-al', 'hydro-mg', 'hydro-ca', 'carb', 'hydroxide-mg', 'aspirin-apap-caffeine-calcium', 'gluconate', 'aspirin-butalbital', 'aspirin-caffeine', 'aspirin-caffeine-butalbital', 'aspirin-cal', 'carb-mag', 'oxide', 'phenyltoloxamine', 'salsalate', 'effer', 'gum', 'apc', 'benoxaprofen', 'choline', 'salicylates', 'liq', 'trisalicylate', 'salicylate', 'cinnamedrine', 'diclofenac', 'diflunisal', 'dihydroxyaluminum', 'aminoacetate', 'ethoheptazine', 'etodolac', 'fenoprofen', 'flurbiprofen', 'ibuprofen', 'indomethacin', 'ketoprofen', 'ketorolac', 'tromethamine', 'im', 'inj', 'trisilicate', 'meclofenamate', 'mefenamic', 'meprobamate', 'methotrimeprazine', 'hydrochloride', 'nabumetone', 'naproxen', 'oxyphenbutazone', 'oxaprozin', 'pamabrom', 'phenylbutazone', 'piroxicam', 'pyrilamine', 'maleate', 'salicylamide', 'thiosalicylate', 'sulindac', 'suprofen', 'tolmetin', 'zomepirac', 'codeine', 'hydrocodone', 'bitartrate', 'oxycodone', 'propoxyphene', 'napsylate', 'acetaminophen-caff-butalbital', 'cod', 'acetaminophen-caffeine-dihydrocodeine', 'mg.', 'buta', 'caff', 'aspirin-caff-butalbital', 'atropine', 'sulfate', 'meperidine', 'buprenorphine', 'hcl', 'butorphanol', 'tartrate', 'nasal', 'dezocine', 'dihydrocodeine', 'compound', 'apap', 'nalbuphine', 'naloxone', 'naltrexone', 'full/half', 'terephthalate', 'pentazocine', 'promazine', 'promethazine', 'alfentanil', 'mcg/ml', 'soluble', 'td', 'sys', 'mcg/hr', 'hydromorphone', 'liqd', 'levomethadyl', 'acetate', 'levorphanol', 'syrup', 'methadone', 'conc', 'dextrose', 'pf', 'oxymorphone', 'sufentanil', 'tramadol', 'relief', 'geneva', 'agonistsa', 'morphineb', 'fentanylc', 'tramadold', '30b', '\\uf06dg', 'adapted', 'v.1.2010', 'agonists', 'agonist-antagonists', 'calculation', 'agonist', 'antidepressant', 'mild', 'potent', 'calculate', 'y', 'consumed', '\\uf06dg/d', 'orala', 'mg/d', 'iv/subqb', 'iv/sub', 'estimates', 'titrate', 'desired', 'foley', 'km', 'nejm', 'we', 'interested', 'things', 'answer', 'circling', 'applies', 'wrong', 'answers', 'fill', 'your', 'birthdate', \"'s\", 'trouble', 'heavy', 'shopping', 'bag', 'suitcase', 'walk', 'shortwalk', 'outside', 'house', 'eating', 'dressing', 'washing', 'toilet', 'were', 'pursuing', 'hobbies', 'leisure', 'breath', 'did', 'rest', 'sleeping', 'felt', 'lacked', 'nauseated', 'vomited', 'constipated', 'little', 'quite', 'bit', 'tired', 'difficulty', 'concentrating', 'reading', 'newspaper', 'watching', 'television', 'feel', 'tense', 'worry', 'irritable', 'depressed', 'remembering', 'has', 'interfered', 'circle', 'how', 'excellent', 'copyright', 'reserved', 'uniform', 'nadir', 'm-component', 'uninvolved', 'flc', 'definite', 'soft', 'plasmacytomas', 'mmol/l', 'solely', 'proliferative', 'pfs=', 'anytime', 'k.', 'engl', 'med', 'landgren', 'weiss', 'bm', 'undetermined', 'ethnic/racial', 'genetic', 'pathogenesis', 'harousseau', 'jl', 'dreyling', 'egw', 'annals', 'suppl', 'ii55-7', 'huang', 'sy', 'yao', 'tang', 'lee', 'wc', 'tsay', 'cheng', 'epidemiology', 'taiwan', 'prevalence', 'qiu', 'wang', 'qi', 'zou', 'zhao', 'epidemiological', 'china', '18-year', 'ash', 'abstracts', 'abstr', 'rajkumar', 'sv', 'richardson', 'pg', 'san', 'miguel', 'barlogie', 'prevention', 'thalidomide-', 'lenalidomide-associated', 'mateos', 'mv', 'schlag', 'khuageva', 'nk', 'shpilberg', 'untreated', 'journal', 'gay', 'larocca', 'petrucci', 'm.', 'achievement', 'melphalan-prednisone', 'based-regimens', 'italian', 'haematologica', 'mitsiades', 'schlossman', 'ghobrial', 'hideshima', 'chen', 'spencer', 'niesvizky', 'attal', 'stadtmauer', 'ea', 'mm-009', 'mm-010', 'kumar', 'sk', 'dispenzieri', 'lacy', 'mq', 'hayman', 'sr', 'buadi', 'fk', 'brenner', 'gondos', 'pulte', 'libby', 'ebaid', 'quintana', 'wiggins', 'mortality', 'workshop', 'paris', 'france', 'kropff', 'bortezomib-', 'hajek', 'delforge', 'mt', 'catalano', 'england', 'medicine', 'v155-7', 'ludwig', 'mccarthy', 'consensus', 'quach', 'prince', 'hm', 'managing', 'making', 'expert', 'fonseca', 'geyer', 'high-', 'poorly', 'responsive', 'hahn', 'wingard', 'jr', 'kc', 'bensinger', 'wi', 'berenson', 'brozeit', 'hematopoietic', 'evidence-based', 'biol', 'allogeneic', 'tian', 'z', 'munshi', 'bioavailable', 'mln9708/mln2238', 'cytotoxicity', 'p21-', 'caspase-8-dependent', 'shaughnessy', 'tricot', 'jacobson', 'zangari', 'anaissie', 'fermand', 'jp', 'katsahian', 'divine', 'leblond', 'v', 'dreyfus', 'macro', 'aged', 'myelome-autogreffe', 'child', 'ja', 'morgan', 'gj', 'davies', 'fe', 'owen', 'rg', 'bell', 'hawkins', 'rescue', 'bolejack', 'van', 'rhee', 'near-cr', 'incorporated', 'up-front', 'tandem', '18s', 'barosi', 'merlini', 'billio', 'boccadoro', 'corradini', 'marchetti', 'sie', 'sies', 'gitmo', 'mmy-3002', 'bortezomibmelphalanprednisone', 'melphalanprednisone', 'abstract', 'fewer', 'greater', 'frontline', 'xii', 'weller', 'lonial', 'jakubowiak', 'jagannath', 'raje', 'i/ii', '15s', 'flinn', 'hari', 'callander', 'noga', 'three-', 'four-drug', 'cyclophosphamide', 'multi-center', 'evolution', 'aj', 'ns', 'jacobus', 'vesole', 'williams', 'open-', 'randomised', 'lancet', 'dick', 'lr', 'second-generation', 'anti-cancer', 'discov', 'jd', 'jr.', 'zhan', 'burington', 'be', 'colla', 'hanamura', 'nair', 'szymonifka', 'hoering', 'profiling-', 'low-risk', 'broyl', 'hose', 'lokhorst', 'de', 'knegt', 'peeters', 'jauch', 'profiling', 'mulligan', 'bryant', 'chng', 'wj', 'roels', 'keats', 'jj', 'chesi', 'schop', 'baker', 'promiscuous', 'activate', 'noncanonical', 'nf-kappab', 'chapman', 'lawrence', 'ms', 'cibulskis', 'sougnez', 'schinzel', 'ac', 'lichter', 'di', 'bacco', 'blakemore', 'berger', 'koenig', 'unreported', 'du', 'huo', 'shi', 'yuan', 'zhang', 'fu', 'factor-', 'coiffier', 'osmanov', 'hong', 'scheliga', 'mayer', 'offner', 'rituximab', 'rituximab-naive', '-sensitive', 'follicular', '52nd', 'exposition', 'orlando', 'fl', 'p.', 'jakob', 'egerer', 'liebisch', 'turkmen', 'zavrski', 'kuckelkorn', 'bergsagel', 'pl', 'drach', 'gutierrez', 'stewart', 'spotlight', 'kastritis', 'christoulas', 'migkou', 'gavriatopoulou', 'gkotzamanidou', 'relapsed/refractory', 'bertsch', 'hielscher', 'der', 'holt', 'vidriales', 'mb', 'montalban', 'perez', 'nc', 'rosinol', 'multiparameter', 'content', 'proliferation', 'spanish', 'gem2000', 'gem2005', '65y', 'pathol', 'terpos', 'g.', 'remodeling', 'healing', 'vs.', 'eur', 'haematol', 'summit', 'nj', 'celgene', 'corporation', 'usp', 'solution', 'columbus', 'oh', 'roxane', 'division', 'boehringer', 'ingelheim', 'september', 'sviggum', 'hp', 'a.', 'dermatologic', 'archives', 'dermatology', 'castaneda', 'cp', 'brandenburg', 'na', 'bwire', 'burton', 'gh', 'zeldis', 'jb', 'multiforme/stevens-johnson', 'syndrome/toxic', 'lenalidomide-', 'js', 'blade', 'ck', 'elice', 'burns', 'mj', 'osteoblastic', 'british', 'haematology', 'yaccoby', 'cavallo', 'osteoblasts', 'heider', 'kaiser', 'muller', 'schulz', 'co', 'osteoblast', 'giuliani', 'morandi', 'tagliaferri', 'lazzaretti', 'bonomini', 'crugnola', 'affects', 'differentiation', 'heath', 'dj', 'rahemtulla', 'zervas', 'chantry', 'anagnostopoulos', 'reduces', 'dickkopf-1', 'activator', 'kappab', 'ligand', 'normalises', 'indices', 'remodelling', 'lan', 'demets', 'dl', 'discrete', 'biometrika', 'u.s.', 'services', 'institutes', 'server', 'dd-mmm-yyyy', 'hh', '14-feb-2013', 'meaning', 'vp']\n",
      "[ 0.00855377 -0.02895105  0.01725     0.02468113 -0.03746993 -0.02942033\n",
      "  0.03868899 -0.03150098 -0.0388348  -0.01438388]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/usr/local/arijit/TA_CBOW_NN/lib/python3.6/site-packages/ipykernel_launcher.py:12: DeprecationWarning: Call to deprecated `__getitem__` (Method will be removed in 4.0.0, use self.wv.__getitem__() instead).\n",
      "  if sys.path[0] == '':\n"
     ]
    }
   ],
   "source": [
    "    # train model\n",
    "model = Word2Vec(var02, min_count=1, size = 10)\n",
    "    # summarize the loaded model\n",
    "print(model)\n",
    "    # summarize vocabulary\n",
    "words2 = list(model.wv.vocab)\n",
    "print(words)\n",
    "     #C16014\n",
    "\n",
    "\n",
    "    # access vector for one word\n",
    "print(model['randomized'])\n",
    "    # save model\n",
    "#model.save('model.bin')\n",
    "    # load model\n",
    "#new_model = Word2Vec.load('model.bin')\n",
    "#print(new_model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "30687"
      ]
     },
     "execution_count": 106,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "open('C16038_cleaned.txt','w').write(str(words2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
